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ABSTRACT
CYTOKINE GENETICS AND EXPRESSION: IMPLICATIONS OF AN
IMMUNOGENETIC PATHOGENESIS IN AUTISM SPECTRUM DISORDERS
Meghan Carey Mott
May 3,2011

Autism Spectrum Disorder (ASD) is an idiopathic pervasive neurodevelopmental
disorder associated with various neuropathologies and immunological dysfunctions.
Cytokines are regulatory proteins that facilitate communication between the immune and
central nervous systems and mediate inflammation, immunity, and hemopoiesis. Previous
literature demonstrates that cytokine expression is altered systemically and in the central
nervous system of individuals diagnosed with ASD when compared to matched
neurotypical controls. Here it is proposed that cytokines are crucial mediators in autism
pathogenesis. The central hypothesis of this research posits that an underlying genetic
susceptibility in cytokine genes is triggered by environmental exigencies (e.g., stress,
infection, ultrasound, hypoxia, pollutant or chemical exposure) during prenatal
development. This hypothesis proposes that the convergence of these scenarios during
vulnerable periods of neurodevelopment ultimately culminates in the autism phenotype.
To test whether cytokines are crucial mediators in autism pathogenesis, the DNA
sequences of 22 single nucleotide polymorphisms (SNPs) within 13 cytokine genes were
genotyped in a cohort of autistic patients and controls. Three SNP frequencies for both
v

pro-inflammatory [ll.IR(+1970)] and anti-inflammatory [ll.A(-590) and IL4(-33)]
cytokine genes were found to be significantly associated with autism incidence.
Next, cytokine mRNA profiles were investigated in post-mortem cortical tissue of eight
autistic subjects and eight matched controls. Transcriptional profiling of cytokine genes
in five post-mortem cortical regions corresponding to Brodmann Areas 4, 9, 17, 22 and
46 indicated heterogeneous expression of cytokine (TNF-a, IL-6, TGFp-l, IL-I P) and
chemokine (lL-8) transcripts in autistic subjects, but these alterations did not reach
statistical significance or reflect values of cortical cytokine translational patterns
established in previous literature. Finally, it was shown that systemic cytokine
translational expression in the blood plasma of children diagnosed with autism disorder
was not modulated with intravenous glutathione administration. These findings indicate
that cytokines play an important role in ASD pathogenesis and reveal possible molecular
mechanisms that warrant future investigation in etiological research. They also show that
the antioxidant agent glutathione, which ostensibly alters cytokine expression at the
intracellular level, does not affect systemic cytokine expression or ameliorate behavioral
outcome when administered exogenously.
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CHAPTER I

Introduction

Autism: Defining the Clinical Phenotype
When the term 'autism' was first introduced in 1912 by Swiss psychiatrist Eugen
Bleuler (1857-1939), it was used to describe schizophrenic behavior. Etymologically, the
word autism is derived from the Greek terms autos, or self, and -ismos, a suffix denoting
an action or state. Bleuler observed several clinical manifestations of autism in his
schizophrenic patients, referring to their dementia as a "detachment from reality with
relative and absolute predominance of the inner life" (Parnas et aI., 2002). Schizophrenics
were often withdrawn and socially inaccessible, and seemed to live in a world of their
own. Bleuler attempted to integrate autism into the diagnostic criteria for schizophrenia.
This goal, however, was never realized as autistic behavior is only present in a subset of
individuals with the disorder, and thus is not considered a core feature of the
schizophrenic pathology.

Instead, autism would come to define a pervasive

developmental disorder demonstrated in pediatric populations only a few years after
Bleuler's death.
As the father of pediatric psychiatry, Leo Kanner (1894-1981) could also be
considered the father of autism research. After his emigration from Austria in 1924,
Kanner soon founded the Johns Hopkins Children's Psychiatric Clinic. In 1938, he began
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studying a group of extremely detached children who had either been diagnosed with
childhood schizophrenia or were considered emotionally disturbed. Five years later,
Kanner published his seminal article "Autistic disturbances of affective contact," in
which he proposed that this group of 11 children, composed of eight boys and three girls
who were all under the age of 11 years old, suffered from a unique syndrome that seemed
to afflict children of highly intelligent parents. He described them as "happiest when left
alone," "like in a shell," with an "anxiously obsessive desire for sameness" and language
that contained innumerable verbal rituals and echolalia which was "not meant to have
communicative value" (Kanner, 1943). Although many of these children had been
diagnosed as 'feebleminded,' Kanner ascertained that they were not cognitively impaired;
on the contrary, they were endowed with excellent vocabularies and uncanny memory for
past events as well as rote memory for precise and complex patterns and sequences.
Kanner concluded that they were suffering from what he termed "early infantile autism,"
and that while it behaviorally resembled many features found in schizophrenia, this
condition had an inherently distinct symptomatology.
At the same time, Hans Asperger (1906-1980), a Viennese pediatrician, noticed a
similar pattern of behavior in four boys referred to him at the University of Vienna
Children's Hospital. In 1944 he published his Habilitation, or second doctoral thesis,
"Autistic psychopathy in childhood," in which he identified behavioral deficits and
abilities in these children that clearly resembled the characteristics Kanner had recently
qualified. Although he described "autistic psychopathy" only one year after Kanner's
article was published, Asperger's contribution remained largely unknown outside of
German literature until it was translated into English in 1991. Once translated, it was
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clear that Asperger's accounts echoed Kanner's. While Asperger focused on milder
manifestations of autism in less affected children, he emphasized that this disorder had a
distinct range of deficits, and was most easily recognizable when it appeared
concomitantly with mental retardation. In his thesis, Asperger described isolated and
"particularly interesting and highly recognizable" children who suffered from "severe and
characteristic difficulties in social integration," extreme clumsiness, "emotional poverty,"
stereotypic movements, "strikingly odd" eye gaze, "a paucity of facial and gestural
expression," and stilted, idiosyncratic language that "feels unnatural" due to their unusual
diction (Asperger, 1991).
Both Kanner and Asperger are considered pioneers of autism research because
they were the first to define the disorder as a distinct and recognizable clinical entity in
the field of pediatric psychiatry. It is certainly interesting that two Austrian physicians on
different continents independently and simultaneously discovered the same disorder and
gave it the same descriptive label. Both authors described their patients as socially
isolated often with aggressive and destructive behavioral problems, clumsy in gait and
gross motor performance, and impaired with language deficits that included the reversal
of pronouns, the tendency to invent words and the use idiosyncratic language. Kanner
and Asperger noted that non-verbal aspects of communication were also impaired, which
included poor eye contact, lack of expressive gestures and odd vocal intonation during
speech. Additionally, they each recognized several other features, namely deficient
imaginative play, repetitive patterns of activities that included stereotyped play and body
movements, fixation on objects and a dislike of environmental change, odd responses to
sensory stimuli, hypersensitivity to noise, and special abilities which usually involved
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rote memory skills. While their behavioral observations were strikingly similar, their
interpretations of the underlying cause of autistic behavior were very different. Kanner
was preoccupied with attributes he thought were shared by parents of autistic children,
namely a "maternal lack of genuine warmth" that led to the conception of 'refrigerator
mothers,' which predominated autism etiological theory in the 1950s (Kanner, 1949).
Asperger, however, considered autism an inherited personality disorder and emphasized
that it had a genetic basis. Both authors noted that these autistic behaviors were much
more common in boys than in girls.
Comparisons of what later became known as Kanner's early infantile autism and
Asperger's syndrome yielded significant disparities between the two otherwise very
similar conditions. Kanner's autism could be apparent in infants as early as six months of
age, whereas Asperger contended that his syndrome was rarely diagnosed until the third
year of life or later. While both physicians agreed that deficiencies in non-verbal
communication and social interaction were distinguishing features of the disorder,
language skills and acquisition differed significantly between them. Kanner's autism was
associated with markedly delayed speech onset, abnormal speech or selective mutism,
while children suffering with Asperger's syndrome could learn good use of grammar and
vocabulary, although the content was often impoverished and inappropriate in social
context and complex meanings were poorly understood (Wing, 1981). Asperger's
accounts maintained that his patients often learned to speak before walking, and that
walking occurred later than normal, while Kanner's observations indicated that walking
developed normally or even earlier than average, while speech developed later or not at
all (Van Krevelen, 1971). These distinctive characteristics between Kanner's early
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infantile autism and Asperger's syndrome led investigators to question whether the two
conditions were simply varieties of the same underlying abnormality or if they were in
fact two separate entities.
Four decades after the initial publication of their seminal articles, research and
clinical findings suggested that a clear distinction between Kanner's autism and
Asperger's syndrome did not exist. While Kanner never acknowledged Asperger's work,
Asperger recognized that there were several similarities between his syndrome and
Kanner's early infantile autism. Subsequent authors agreed that the two conditions could
be differentiated, but that they were more alike than different, and thus could not be
considered mutually exclusive diagnostic categories (Van Krevelen, 1971; Wolff &
Barlow, 1979). Their dissimilarities were interpreted as variations in severity of the same
clinical behavioral pattern, where individuals with Asperger's syndrome showed fewer
signs and were less severely affected than those with Kanner's autism. Investigators
recognized hallmark behavioral discrepancies between the two similar disorders:

"Children who do not talk or who parrot speech and use strange idiosyncratic
phrases, who line up toys in long rows, who are oblivious to other people, who
remember meaningless facts - these will rightly conjure up Kanner's memory.
Children and adults who are socially inept but often socially interested, who are
articulate yet strangely ineloquent, who are gauche and impractical, who are
specialists in unusual fields - these will always evoke Hans Asperger's name."
(Frith, 1991)
Although Kanner's autism and Asperger's syndrome had somewhat different profiles of
cognitive, language and motor functions, it was posited that they could be considered
subclassifications on the same 'autistic continuum' (Wing, 1988). Lending further
support to this argument, the same individual who was considered autistic in early life
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could be diagnosed with Asperger's syndrome in adolescence and adulthood (Wing &
Gould, 1979).
Currently, the Diagnostic and Statistical Manual for Mental Disorders (DSM)
defines autism as a pervasive developmental disorder which manifests during the first
three years of life and is qualified by a triad of impairments in reciprocal social
interactions, the development of communication, and severely restricted, stereotyped and
repetitive patterns of interests and behaviors (American Psychiatric Association, 2000).
To account for the variations of deficiencies and abilities that are present in affected
individuals, the DSM considers autism a spectrum disorder, where sUbtypes are
categorized for diagnostic purposes. The three sUbtypes that compose the autism
spectrum include: autistic disorder, Asperger's disorder, and pervasive developmental
disorder not otherwise specified (PDD-NOS).
Autistic disorder is defined as classic autism, essentially the same condition
identified by Kanner. Qualitative impairments in social interaction are often manifested
as marked impairments in eye-to-eye gaze or communicative gestures, inappropriate or
limited facial expressions, failure to develop peer relationships at the appropriate
developmental level, a lack of spontaneous seeking to share enjoyment or interests with
others, and a lack of social or emotional reciprocity. Communicative impairments often
include a delay in or lack of spoken language, impairment in the ability to initiate or
sustain a conversation, and stereotyped or repetitive use of language or idiosyncratic
language. Manifestations of restricted and repetitive patterns of interests or behaviors
frequently include an encompassing preoccupation with a subject of interest that is
abnormal in intensity, an inflexible adherence to routines or rituals, stereotyped and
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repetitive motor mannensms (e.g. hand flapping or twisting or complex whole-body
movements) and a preoccupation with parts of objects. In order for a subject to be
diagnosed with autistic disorder, a total of six of the abovementioned items must be
present with at least two in the category of social interaction, and one per category of
communication and restricted/repetitive behaviors or interests.
Criteria for diagnosis of Asperger's disorder and PDD-NOS are very similar to
those of autistic disorder, although behavioral differences are apparent. In Asperger's
disorder, qualitative impairments in social interaction and manifestations of restricted and
repetitive behaviors or interests are similar to those that typify autistic disorder; however,
no clinically significant general delay in language or cognitive development is present.
PDD-NOS is considered 'atypical autism', where individuals do not meet criteria for
either autistic or Asperger's disorder but do present with severe or pervasive impairments
in social interaction, verbal or non-verbal communication, or have the restricted or
repetitive behaviors or interests previously mentioned. Although these subjects exhibit
autistic symptomatologies, these are usually atypical, subthreshold, or occur at a late age
of onset and thus cannot be classified as either autistic or Asperger's disorder. For a
complete and thorough review of diagnostic criteria for each subgroup contained with the
autism spectrum, please refer to the appendix.
As the abovementioned DSM criteria demonstrates, diagnosing autism spectrum
disorders (ASDs) can be challenging since it is solely based on behavioral and
developmental observation. Research indicates that at age two, an ASD diagnosis can be
considered very reliable (c. Lord et ai., 2006). The American Academy of Pediatrics
recommends that pediatricians screen children for ASDs at 18 months and 24 months of
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age. There are a variety of screening tools available for health care professionals to assess
the general development of ASDs. Many incorporate parent reports to increase provider
observation of the child's development and promote parent awareness of developmental
milestones and disabilities. Examples of parent questionnaires or parent-completed
screening tools used to diagnose developmental delays include the Ages and Stages
Questionnaires, Communication and Symbolic Behavior Scales, Parents' Evaluation of
Developmental Status, Modified Checklist for Autism in Toddlers, and the Screening
Tool for Autism in Young Toddlers. Additionally, specialists often screen for ASD
diagnosis using one of the following assessments: the Autism Diagnostic InterviewRevised (ADI-R), Autism Diagnostic Observation Schedule-Generic (ADOS-G),
Childhood Autism Rating Scale (CARS), and the Gilliam Autism Rating Scale-Second
Edition (GARS-2). Pediatric specialists rely on parent interviews and direct observation
of the child using standardized autism assessments specific for cognitive and adaptive
functioning. While each of these tests has a different method of evaluation, studies have
shown that their screening measures have sensitivities and specificities greater than 70%
(Committee on Children and Disabilities, 2001).
The reliability of parent-completed screening tools in addition to inter-test
diagnostic agreeability and validity represent significant limitations in the consistency of
ASD classification assessment. Early intervention programs improve long-term function
in children diagnosed with an ASD (D. Dawson & Osterling, 1997). Thus, conflicting
diagnoses from different professionals can have significant academic, behavioral and
social consequences for the individual child. Evidence indicates that the ADI-R and
ADOS-G are the most accurate and reliable assessments available for identifying autism;
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however, most evaluators do not use these measurements due to the fact that they are
more expensive and require more time and training to administer (c. Lord et aI., 2000;
M. E. Williams et aI., 2009). Cultural and socio-economic status can delay access to
diagnostic services available to affected families, make assessment difficult, and result in
diagnostic errors (Mandell et aI., 2002). An examination of the practices used to evaluate
ASDs found that different service systems, measured at public schools, programs
evaluating eligibility for developmental disabilities services, and hospital-based programs
agreed on ASD diagnosis in the same individual only 45% of the time (M. E. Williams et
aI., 2009). These discrepancies in diagnosis may be a reflection that professionals do not
follow best practice guidelines for assessment of ASDs, and carry significant implications
regarding ASD diagnostic criteria measured using different tools by different
professionals.

Epidemiology of ASD
The first epidemiological study of autism surveyed 78,000 urban British children
aged 8-10 years old between 1963-64, and estimated a prevalence rate of 4.5 per 10,000
(Lotter, 1966). At that time, Kanner's definition of early infantile autism provided the
only behaviorally defined criteria for ascertaining the presence of 'autistic conditions.'
Thus, this survey's estimate of prevalence may not represent the most accurate estimate
of a syndrome poorly defined relative to current standards. Since then, numerous studies
have been performed attempting to estimate prevalence of ASDs in countries world-wide,
including Australia, Canada, China, Denmark, Finland, France, Germany, Iceland, India,
Indonesia, Iran, Ireland, Israel, Japan, Norway, Oman, Singapore, South Africa, Spain,
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Sweden, the United Arab Emirates, the United Kingdom, and the United States.
Comparison between studies is challenging due to variations in diagnostic assessment
tools used and well as changes in diagnostic criteria defined in successive publications of
the DSM and the International Classification of Diseases (lCD). Subsequently, it is
difficult to assess changes in prevalence rates of ASD over time and in different
countries, and even more challenging to extrapolate whether the actual incidence of ASD
is related to ethnicity, geographic location, or year of evaluation.
A review of 22 non-overlapping epidemiological studies conducted in 12
countries between the years of 1966-1998 reported a prevalence estimate of 4.4 per
10,000 people diagnosed with autism (Fombonne, 1999). This study found a significant
correlation between prevalence rate and year of publication, indicating an increase in
prevalence estimates in the 1990s compared to previous decades. The author suggests this
increase reflects "an improved recognition and detection of autism together with a
broadening of the diagnostic concept and definitions," rather than a true increase in
incidence of the disorder (Fombonne, 1999). This review also found a clear association
between autism and mental retardation, a significant gender bias where males were
approximately 4 times more likely to be affected than females, an association with autism
and rare or genetic medical conditions, and no association between autism and social
class or parental education. Interestingly, all of the studies surveyed also identified a
larger group of children who did not meet diagnostic criteria for autism but qualified for a
pervasive developmental disorder.
In contrast to autism studies, very few epidemiological inquiries regarding
Asperger's syndrome were investigated until several years later. The first study,
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performed in Sweden in 1977, originally estimated a prevalence for Asperger syndrome
in seven-year-old children to be 26 per 10,000 (c. Gillberg et aI., 1982). Also in the
1970s, British investigators estimated that 1.1 per 10,000 children under the age of 15
years old in London who had been diagnosed as autistic early in life were later diagnosed
with Asperger's syndrome (Wing & Gould, 1979). In 1985, another Swedish study
estimated the population frequency of Asperger's syndrome in 10,500 children aged 7-16
years old to be 8 per 10,000 (I. C. Gillberg & Gillberg, 1989). Years later, the same
Swedish group studied 1,519 7-16 year old children in the same area and estimated the
prevalence of Asperger's syndrome to be 28.5 per 10,000; however, their confidence
intervals were very large and thus this data should be considered imprecise (Ehlers &
Gillberg, 1993). While these early studies suggested that the prevalence of Asperger's
syndrome was higher than that for autism, recent findings indicate that prevalence rates
of Asperger's syndrome are actually significantly lower (Chakrabarti & Fombonne, 2001;
Ellefsen et aI., 2007; Kadesjo et aI., 1999; Powell et aI., 2000; Sponheim & Skjeldal,
1998).
Follow up epidemiological studies of ASD estimated autism prevalence rates for
surveys published between 1966-1991 to be 4.411 0,000 while these rates increased to 911/10,000 between the years of 1992-2001, with the most recent estimation being
20/10,000 within the last decade (Fombonne, 2001, 2009). In the 1990s, average

prevalence estimates for PDD-NOS were approximately 15/10,000 and the rate of
Asperger's syndrome was consistently lower, at 2.5/10,000 (Fombonne, 2001). Within
the last decade these values have increased to 30/10,000 for PDD-NOS and 6/10,000 for
Asperger's syndrome (Fombonne, 2009). These apparent increases in ASD prevalence
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rates cannot be directly attributed to increases in incidence of the disorder, however.
Research suggests that variability in prevalence of ASDs across studies can be explained
by differences in diagnostic criteria, case-finding method and issues of study design
(Posserud et ai., 2009; J. G. Williams et ai., 2006). Referral trends over time are affected
by heightened public awareness, availability of diagnostic services, changes in referral
patterns, decreasing age at diagnosis, and changes in diagnostic concepts and definitions.
Thus, there are multiple confounding factors in ASD prevalence estimate investigations
and comparison between studies is problematic. Ideally, repeated surveys that use the
same diagnostic tools, performed in the same geographic locations at different periods of
time would yield the most accurate prevalence estimates of ASD.
Although evaluating ASD prevalence over time is challenging, epidemiological
evidence collected within the last decade suggests that incidence of the disorder is
increasing. The Centers for Disease Control and Prevention (CDC) conducted a
surveillance study in 2006, which estimated that 1% or one child in every 110 aged 8
years old in the United States is currently diagnosed with an ASD (Centers for Disease
Control and Prevention, 2009). Compared to data they collected in 2002, this represented
at 57% increase in the average prevalence of ASD measured at the same locations
throughout the country (Centers for Disease Control and Prevention, 2007). These sites
included areas in Alabama, Arizona, Colorado, Georgia, Maryland, Missouri, North
Carolina, Pennsylvania, South Carolina, and Wisconsin. Every site except Colorado
reported a significant increase in identified ASD prevalence within all major sex,
racial/ethnic and cognitive functioning categories (Centers for Disease Control and
Prevention, 2009). Interestingly, these increases were more attributable to autism
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diagnosis rather than broader ASD diagnoses (e.g., PDD-NOS or Asperger's syndrome).
ASD prevalence estimates of 1% in the United States match recent estimates provided by
groups in the United Kingdom and Canada (Baird et aI., 2006; Baron-Cohen et aI., 2009;
Lazoff et aI., 2010). The most recent estimate of ASD prevalence was performed in 2007
by the Health Resources and Services Administration's Maternal and Child Health
Bureau. This report surveyed over 78,000 children, and found that 1.1 % or one child out
of 91 in the United States aged 3-17 years old is currently diagnosed with an ASD
(Kogan et aI., 2009). This study also found a ma1e-to-fema1e ratio of approximately 4: 1,
and higher ASD prevalence among single mothers and non-Hispanic white children. One
limitation of this study that should be mentioned, however, is that it was based on parentreports of diagnosis, which were not externally validated.
Comparative analysis indicates that ASD prevalence estimates are associated with
geographic region. Studies performed outside North America and Europe show
significantly lower prevalence estimates for ASDs (AI-Farsi et aI., 2011; Honda et aI.,
2005; Zhang & Ji, 2005). One study compared estimates reported for children born
between the years of 1994-1999 within Denmark and Western Australia, and found that
overall ASD prevalence rates were significantly higher in Denmark (Pamer et aI., 2011).
It is likely that these differences are due to diagnostic assessment tools and service

availability associated with each country. Children in Western Australia are not routinely
screened for developmental disabilities as they are in Denmark. Assessments and services
are also free in Denmark, whereas individual families are financially responsible for the
same services in Western Australia. Studies comparing ASD prevalence rates between
countries are only just beginning, and preliminary results indicate that significant
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differences exist (Zaroff & Uhm, 2011). Interpretation of this analysis will prove
complicated because

In

addition to differences in diagnostic assessment tools and

serVIces, investigators must also take into consideration the effects of culture on
information processing specifically regarding social interaction, a core feature in ASD
symptomatology. It is also possible that environmental and/or geographical differences
could account for disparities in prevalence estimates between countries. Increased
prevalence rates indicate that environmental influence plays a particularly significant role
in the incidence of ASD, and that research into viable environmental etiologies is
warranted.
Regardless of differences in prevalence rates across countries and ethnicities,
evidence suggests that ASD incidence may be increasing. One fact IS becoming
progressively clearer: pervasIve developmental disorders are not rare and should be
considered an urgent public health concern. Future epidemiological studies should aim to
be longitudinal in their analysis of the same geographic location, and make sure to use the
same screening tools and diagnostic criteria for assessment. Additionally, population
studies performed in different countries should aim to standardize assessment tools in
order to make inter-study comparison more feasible. Until then, estimates of ASD
prevalence according to birth date and geographic location will prove difficult, and few
conclusions can be made regarding changes in incidence rates through time.
It is estimated that American society spends $35 billion annually in direct and

indirect costs associated with autism treatment (Ganz, 2006). Direct costs are based on
medical and nonmedical expenditures. Direct medical expenses include physician,
emergency

and

other

professional

serVIces,
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behavioral

therapies,

prescription

medications, equipment and other supplies, and medically related travel and time costs.
Special education, childcare, home and vehicle modifications, and supported employment
services are examples of direct nonmedical expenses. Indirect costs are qualified as loss
of productivity measured in income associated with individuals with autism and their
caregivers, due to missed work hours, switching to jobs that are lower paying but more
flexible, and loss of employment. Age-specific autism data show that direct medical costs
are highest for the first five years of life where behavioral therapies are the largest
contributor, and that adult care represents the largest lifetime direct cost (Ganz, 2007).
Compared to lifetime estimates of direct medical costs for typical Americans, this means
that individuals with autism spend twice as much, and spend it at a much younger age
(Alemayehu & Warner, 2004). Clearly these financial burdens are daunting, not only for
the families of affected individuals, but also for society in general. Taken together,
studies that suggest increased incidence combined with significant annual individual and
societal cost estimates indicate that etiologic and preventative research in ASD is
imperative.

Neuroanatomical and Neuropathological Features
Magnetic resonance imaging (MRI) and postmortem neuropathological studies
indicate that ASD is characterized by dynamic age-specific structural and functional
abnormalities. Developmental heterochronicity, wherein various brain regions grow at
different rates compared to controls, is a defining anatomical feature associated with the
disorder (Carper & Courchesne, 2005; Carper et aI., 2002; Courchesne et aI., 2001;
Sparks et aI., 2002). Topographic change caused by developmental heterochronicity
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likely produces the cytoarchitectural alterations that delineate a distinct neuropathology
in autism. The extent of deviation from the normal trajectory of brain development may
be used as a diagnostic tool of subtype specificity in the future (Courchesne et aI., 2003).
Impairments in both local and global connectivity have been described, with an overdevelopment of local connectivity networks at the expense of long distance connectivity
(Casanova et aI., 2006; Courchesne & Pierce, 2005). The developmental abnormalities
that typify ASD, outlined below, are sources of structural and functional change that
generate the clinical phenotype.
Young children with ASD are macrocephalic and macroencephalic, two features
which manifest prior to and during the time clinical diagnosis is ascertained. Longitudinal
studies have shown that at birth, head circumferences of ASD children are significantly
smaller than those of neurotypical children, but that by 6-14 months of age ASD head
circumferences are significantly larger (Courchesne et aI., 2003). Head circumference
values are considered an accurate index of brain size, and MRI-based studies reveal that
autistic children have significantly increased brain volumes compared to controls
(Bartholomeusz et aI., 2002; Piven et al., 1996). Brain volumes of autistic children
increase the most between the ages of 2 and 4.5 years, where cerebellar and cerebral
white matter (WM) accounts for the majority of growth (Courchesne et aI., 2001). This
macroencephaly does appear to have regional specificity, but volumetric studies are
inconsistent in their findings. For example, one study indicated that the greatest increase
in WM volume takes place in the frontal lobes, and the least in the occipital lobes (Carper
et aI., 2002). Still others report that the greatest generalized volume increase occurs in the
occipital and parietal lobes (Filipek, 1996; Piven et aI., 1996). Brain growth acceleration
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precedes and is associated with the onset of clinical symptoms, and the specific pattern of
growth reflects the severity of ASD diagnosis (Courchesne et aI., 2003; G. Dawson et aI.,
2007; Dementieva et aI., 2005). ASD brain growth trajectories appear to decelerate after
the first year of life, plateau during adolescence, and be comparable to controls in
adulthood (Redclay & Courchesne, 2005). The functional consequences of abnormal
brain development observed in autism explain many of the behavioral characteristics that
define the disorder (I. L. Cohen, 2007). Although adult brain sizes are comparable
between autistic subjects and matched controls, a core neuropathology remains present,
and indicates that functional connectivity in different regions is diminished.
MRI-based studies reveal multiple distinguishing neuranatomical features
associated with autism, and the foremost of these involves a significant increase in WM
volume. While WM makes up less than a third of total cerebral volume, it accounts for
65% of the volume increase reported in the brain tissue of autistic subjects over controls
(Herbert et aI., 2003). After adjusting for total brain volume, autistic subjects maintain a
significantly greater WM volume compared to age-matched controls, which suggests that
this WM volume increase is a specific feature associated with autism rather than a
reflection of macrocephaly (Bigler et aI., 2010; Herbert et aI., 2003). When cerebral WM
areas were parcellated into an outer zone of radiate WM composed of intrahemispheric
corticocortical connections and an inner zone of bridging and sagittal compartments, the
outer radiate WM was increased in all cerebral lobes with frontal lobe predominance
while the inner zone WM showed no increase in autism (Herbert et aI., 2004). Relative
reduction in various areas of the corpus callosum is a consistent finding in autism when
compared to controls (Hardan et aI., 2000; Hardan et aI., 2009; Piven et aI., 1997). As
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with findings in overall brain enlargement, WM concentrations are not as large compared
to controls in older autistic individuals (Chung et al., 2004; Waiter et al., 2005). The
overgrowth of specific WM regions is part of a pathologic process that disrupts the
development of normal brain structure and function in autism, although the underlying
molecular mechanisms by which this occurs are currently not understood.
Volumetric analyses indicate that abnormalities in multiple cortical and
subcortical structures are associated with autism. The limbic system, known for its role in
emotion, memory and motivation, is consistently affected. Several studies report
reductions in the size of the amygdala and hippocampus in autistic subjects, as well as
poorer performance on neuropsychological tasks associated with each structure (Aylward
et aI., 1999; Herbert et aI., 2003; Loveland et aI., 2008; Saitoh et aI., 2001). Still other
studies report that children with autism have larger hippocampi compared to controls,
while the amygdala is enlarged in only young autistic children (Schumann et aI., 2004).
While these limbic structures may be larger in autistic children, they have been found to
be smaller in adults when compared to controls (Aylward et aI., 1999). Thalamic
abnormalities have also been observed, and include increased cell packing density,
decreased cell size, and an overall decrease in thalamic volume in autistic individuals
(Hardan et aI., 2006; Schultz et aI., 1999; Tsatsanis et aI., 2003). Increased parietotemporal lobe and cerebellar hemisphere volumes are associated with autism (Brambilla
et aI., 2003). Overgrowth of the frontal and temporal lobes and amygdala are
synchronized with the abnormally accelerated brain growth that occurs between the ages
of 2-4 years in autistic children (Carper et aI., 2002; Hazlett et aI., 2005; Sparks et aI.,
2002). While cortical thinning typically occurs with age, this process appears to be
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accelerated in autistic individuals (Hustler et aI., 2007). According to voxel-based MRI
analysis, gray matter is reduced in a regionally specific manner and CSF total volume is
significantly increased in autistic patients when compared to controls (McAlonan et aI.,
2005). Other studies report gray matter volumetric increases in specific areas in autism
(Rojas et aI., 2006). While some MRI studies have produced discordant findings, they
reveal a deregulation of brain growth in early childhood in autism, wherein growth
trajectories are atypical and regionalized.
The first studies to reveal neuropathological changes in autism were performed in
the 1980s by numerous groups (Bauman & Kemper, 1985; Courchesne et aI., 1988;
Gaffney et aI., 1987; Ritvo et aI., 1986). Five neuropathological features, in particular, are
associated with autistic disorder l : increased brain weight and WM volume during
childhood, reduced neuronal size and increased cell packing density in the forebrain
limbic system, reduced numbers of Purkinje cells in the cerebellum, age-related changes
in cell size and numbers in the nucleus of the diagonal band of Broca, deep cerebellar
nuclei and inferior olive, and malformations of cerebral cortex and brainstem (Bauman &
Kemper, 2005). The most consistent finding across postmortem studies in autism is the
significant decrease in cerebellar Purkinje cells when compared to controls (Arin et aI.,
1991; Bailey et aI., 1998; Ritvo et aI., 1986). Purkinje cells are also smaller in size in
autism compared to age and sex-matched controls (Fatemi et aI., 2002). Abnormalities in
size and number of neurons in the fastigeal, globose and emboliform nuclei have also

1 As a cautionary note, postmortem neuropathological studies in autism are based on
reports of a very small number of brains. Due to the broad age spectrum as well as
clinical diversity of ASD, the pattern of neuropathological changes is incomplete and
inconsistent. Thus, the morphological markers and neuropathological diagnostic criteria
of autism have not been established.

19

been shown, and appear to change with age (Bauman & Kemper, 1994). What follows is
a summary of the collection of neuropathological features in autism that have been
observed by different groups.
Cortical and sub-cortical morphological abnormalities associated with autism
primarily involve the limbic system. Histological studies have shown that the
hippocampus of autistic individuals has reduced cell size and simplified dendritic
branching compared to age-matched controls (Raymond et aI., 1996). Evidence of
neuronal cell size and packing density in autistic amygdale is contradictory. While some
studies report a reduction in neuronal size and increased cell packing densities, others
find no significant difference in cell size but do report significantly fewer neurons
associated with the amygdala of autistic patients (Bauman & Kemper, 1990; Schumann
& Amaral, 2006). Cell packing density was reportedly increased in the hypothalamus and

mamillary body (Bauman & Kemper, 1985). Smaller neurons have been reported in the
basal ganglia and cerebellum of 4- to 7-year-old children with autism, specifically in
Purkinje cells, the dentate nucleus, amygdala, nucleus accumbens, caudate and putamen,
with corrections in size by adulthood (Wegiel et aI., 2008). A generalized reduction in
density ofaxons and dendrites in the autistic brain has also been proposed (Guerin et aI.,
1996). These studies indicate that a delay of neuronal growth evidenced by cortical
dysgenesis, which is brain structure-specific, occurs in autism and undergoes
modification during the life span.
Several brain stem and cerebellar morphological abnormalities have been revealed
in neuropathological studies on autism. Neurons in the inferior olivary nucleus appear
more abundant in autism, but their size varies with age in that they are enlarged in
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children younger than 12 years old but smaller in adults over 21 when compared to agematched controls (Anderson et aI., 1993; Kemper & Bauman, 2002). The pons, medulla,
and midbrain midsagittal areas are all smaller in autistic subjects, and the pons seems to
develop more rapidly in autism compared to controls (Hashimoto et aI., 1995). As
mentioned previously, the cerebellum is the most consistent site of neural abnormality in
autism. Alterations in Purkinje cell density and number appears to be more prominent in
specific regions (Arin et aI., 1991). Hyerplasia and hypoplasia in cerebellar vermal
regions is evident (Courchesne et aI., 1994). These studies indicate atrophy of the
neocerebellar cortex, with regionally specific marked loss of Purkinje cells.
Neocortical rninicolumns, the basic architectonic and functional units of the
human brain that organize neurons in cortical space, are smaller, more numerous, and less
compact in autistic patients compared to controls (Buxhoeveden & Casanova, 2002;
Casanova et aI., 2002; Casanova et aI., 2006). While this minicolumnar pathology has
been observed bilaterally in Brodmann cortical areas 3,4,9, 17, 21 and 22, the narrowest
minicolumns are found in the dorsolateral prefrontal cortex of autistic subjects (Casanova
& Trippe, 2009; Casanova et aI., 2006). Reduction in size of neocortical neurons and

their nuclei is likely an indicator of reduced or impaired functional connectivity between
distant cortical regions with a bias toward local rather than global information processing
(Casanova et aI., 2006; Just et aI., 2004; Koshino et aI., 2005). Reductions in corpus
callosum and gyral window size confirm that a constrained cortical network of
connections exists, which favors short-range corticocortical fibers at the expense of longrange commissural fibers (Casanova et aI., 2009). Malformations of cortical development
have been observed in disorders caused by abnormalities of cell proliferation, apoptosis,
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cell migration, cortical organization and axon pathfinding (Hevner, 2007). Thus, the
minicolumnar abnormalities seen in autistic individuals suggest that the cause of the
underlying pathology likely occurs during fetal or very early postnatal development.
Studies of clinicopathological correlations in autism reveal a link between several
domains of functional deficits and primary neuropathology. One of the core features of
ASD symptomatology involves deficient verbal abilities related to the understanding of
semantics and social pragmatics (Wetherby et aI., 1998). Studies of language-related
neocortex reveal reduced neuronal density in Wernicke's area (BA 22) and gyrus
angularis (BA 39) and increased glial cell density in both of these regions as well as in
Broca's area (BA 44) in autistic subjects when compared to controls (Lopez-Hurtado &
Prieto, 2008). Investigators hypothesize that structural alterations in language-related
cortical areas contributes to the communication impairment in autism.
Another core feature of ASD behavior includes abnormalities in social
reciprocity, eye contact, and facial expression. It has been established that patients with
autism have deficits in face processing, perception and recognition (Grelotti et aI., 2001;
Joseph & Tanaka, 2003). Functional magnetic resonance imaging (tMRI) studies have
shown that the fusiform gyrus, which is involved in face-processing, is hypoactive in
autistic patients (Pierce et aI., 2004). It is believed that this hypo activation is associated
with the failure of autistic subjects to make direct eye contact (Dalton et aI., 2005).
Neuropathological studies reveal reduced neuronal number and volume in the fusiform
gyrus and suggest that an underdevelopment of connections between primary visual
cortex (BA 17) and the fusiform gyrus may contribute to abnormal face perception in
autism (van Kooten et aI., 2008).
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Impairments in gross and fine motor function as well repetitive and stereotyped
behaviors are common findings in patients with autism. It has been proposed that
sensorimotor deficits may be associated with pathological changes in the basal ganglia
and cerebellum (Bailey et aI., 1998; Sears et aI., 1999). A positive correlation between
caudate volume and repetitive behavior scores has been reported in autism (Hollander et
aI., 2005). Cerebellar findings including a decrease in the number of GABAergic
Purkinje cells and increased feed-forward inhibition from basket cells indicate altered
inhibition of cerebellar nuclei which could directly affect cerebellocortical output and
lead to changes in motor behavior and cognition (Arin et aI., 1991; Yip et aI., 2008).
A particular range of cognitive deficits in autism demonstrate that performance IQ
is generally higher th,m verbal IQ and that comprehension is usually low on intelligence
tests (Siegel et aI., 1996). These cognitive deficits are likely related to abnormalities in
the memory and limbic systems. Size reductions in the hippocampal formation and
amygdala in autism have been reported, as well as reduced complexity of dendritic arbors
in the hippocampus (Aylward et aI., 1999; Bauman & Kemper, 1985). The anterior
cingulate gyrus is reduced in volume and positron emission tomography (PET) activity in
subjects with autism is decreased (Haznedar et aI., 1997). The caudate nucleus is
involved in learning, short- and long-term memory, planning and problem solving, thus
observed caudate volume changes in autistic children may also explain cognitive deficits
that typify autism (Fuh & Wang, 1995; Poldrack et aI., 1999; Schmidtke et aI., 2002).
Neuroanatomical and neuropathological studies have revealed an atypical pattern
of development in ASD. The brains of autistic subjects are generally larger during the
onset of clinical symptoms when compared to controls, where WM contributes
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disproportionately to brain volume enlargement in a regionally specific manner.
Developmental heterochronicity is a defining feature of ASD, however inconsistencies in
findings make cross-study comparison difficult. Multiple factors account for these
inconsistencies, most notably among them conflicting subject diagnostic and
exclusionary criteria. Statistical problems also exist in data collection, due to small
sample size, confounding factors such as co morbidity with other disorders, IQ,
postmortem interval, cause of death and medication history. While discordant findings
exist, it is clear that characteristic neuropathologies are associated with the core
symptoms of ASD. Image analysis can be used to distinguish subjects with autistic
disorder, Asperger's syndrome or PDD-NOS from controls, which may yield significant
diagnostic applications (Akshoomoff et ai., 2004; EI-Baz et ai., 2007). Generalized
processing abnormalities related to a constrained neural network underlie the observed
and defining behaviors found in ASD and lead to the idea of autism as a neural
information processing disorder (Gustafsson, 1997; Happe et ai., 2001; Herbert, 2005).
Precisely how these neurobiological abnormalities relate to the behavioral phenotype is
currently under investigation. Taken together, these findings suggest that while
abnormalities seen in the brains of autistic individuals represent an ongoing
neuropathology that continues to change through adulthood, this process has a
neurodevelopmental component that may be prenatal in origin.

Concept of Inflammation
The immune system serves as a sentinel against foreign invasion, injury, and
aberrant cell growth, and propagates the appropriate response necessary to eliminate
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foreign antigens, facilitate tissue repair, and maintain homeostasis. The immune response
can be divided into two basic components: innate immunity and adaptive immunity.
Innate immunity is often referred to as the first line of defense in the host immune system
because it is stimulated by common structures shared by groups of microbes. Once
microbial presence is recognized, a programmed immunological response is initiated. In
the case of a pathogen invasion, for example, innate immune cells recognize pathogenderived molecular patterns (PAMPS) and molecular patterns from injured tissue via the
pattern recognition receptors (PRRs) in their cell membranes. Toll-like receptors (TLRs)
are a class of PRRs that are well defined and one of the most conserved components of
the innate immune system. The principal components of the innate immune system
include physical and chemical barriers, phagocytic cells, natural killer (NK) cells, blood
proteins, and cytokines (Abbas et aI., 2007). The adaptive immune system is sometimes
referred to as the acquired or specific immune system, due to its ability to distinguish
between closely related antigens, and the fact that its protective responses are acquired
with experience. The main components of the adaptive immune system include
lymphocytes and their secreted products, including antibodies. There are two types of
adaptive immune responses: humoral and cell-mediated. Humoral immunity is mediated
by antibodies, which are produced by B lymphocytes. These antibodies recognize and
target extracellular microbes for elimination by effector cells and molecules (e.g., the
complement system). Cell-mediated immunity is mediated by T lymphocytes and their
products, which include cytokines. These cells recognize and target infected host cells for
elimination,

thus

protecting

the

host

from

intracellular

microbial

infection.

Phylogenetic ally, the innate immune system is older than the adaptive immune system,
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which has become increasingly more specialized in more highly evolved species. Both
innate and adaptive immune systems function cooperatively in order to maintain an
integrated system of host defense.
Inflammation is a cellular reaction of immunity, triggered by injury or infection,
which is characterized by vasodilation along with the concurrent recruitment of local
immune and chemical mediators acting in concert to eliminate infectious agents and
restore homeostasis. Inflammation can result from either innate or adaptive immune
system responses. Although it is commonly considered a protective mechanism used to
control injury or infection and promote tissue repair, inflammation can also cause tissue
damage and disease. In the classical pathogen-initiated inflammatory response, tissueresident macrophages and mast cells recognize signs of infection and produce a variety of
inflammatory mediators; including cytokines and chemokines. Cytokines are a group of
regulatory proteins that play vital roles in cellular communication during both the innate
and adaptive immune responses. Chemokines are a family of structurally homologous
small cytokines that stimulate leukocyte movement and regulate their migration from
blood into tissue. Both cytokines and chemokines serve as mediators of inflammation,
immunity, and hemopoiesis. When resident immune cells encounter pathogens in the
local area, they release cytokines that activate and recruit circulating leukocytes to the
site of infection. Recruitment, and thereby the acute-phase immune response, is possible
due to the fact that cytokines cause the postcapillary venules in the activated endothelium
of local blood vessels to become selectively permeable to leukocyte (mostly neutrophil)
extravasation (Medzhitov, 2008). This selectivity is based on the distinct expression of a
combination of adhesion molecules and chemokine receptors that exist on neutrophils
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and monocytes. In this way, systemic immune cells are allowed access to the infected
area so that they can recognize and ingest bound microbes by the process of
phagocytosis. Once ingested, the phagosome fuses with lysosomes, creating the
phagolysosome. It is within the phagolysosome that microbicidal mechanisms occur.
Activated neutrophils or macrophages ultimately destroy microbes with the proteolytic
enzymes, reactive nitrogen intermediates, or highly reactive oxidizing agents that are
contained in their phagolysosomes.
In an acute inflammatory response, once neutrophils reach the site of injury or
infection, they kill any pathogen or antigen-presenting cell (APC) with which they come
into contact by releasing the toxic contents of their granules (Nathan, 2002, 2006). If the
acute response is successful, the pathogen is destroyed and a tissue repair phase is
initiated by anti-inflammatory lipoxins, which recruit monocytes to the area that produce
another cytokine: transforming growth

factor-~ (TGF-~).

Together they serve to remove

dead cells and begin the tissue remodeling process (Serhan & Savill, 2005). If neutrophils
are unable to destroy the pathogen, they are replaced with macrophages and T cells, and
chronic inflammation may occur in which granulomas are produced from layers of
macrophages and T lymphocytes that cluster together and form walls in order to contain
infection and protect the host (Abbas et aI., 2007). The mechanisms of infection-based
inflammation are well defined compared to inflammation caused by other conditions,
particularly chronic inflammatory states. Systemic chronic inflammation seems to be
caused by different instigators and characterized by different physiologic mechanisms
that are not related to those seen in the acute inflammatory response. For this reason, it
has been proposed that the standard view of inflammation as a reaction to infection or
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injury should be expanded to account for such inflammatory processes (Medzhitov,
2008).

Resident CNS Immune Cells and Their Role in Neuroinflammation
Neuroinflammation is characterized by the activation of resident immune CNS
cells, the expression of proinflammatory mediators, and the infiltration of various cellular
components from the peripheral immune system. Although it was once considered an
immune-privileged site because of the existence of the blood brain barrier (BBB),
accumulating evidence shows that the CNS is capable of immune and inflammatory
responses reminiscent of those seen systemically (Rivest, 2009). While pathogen-specific
immune responses are limited because the lymphatic system does not extend into the
brain, rapid responses to immune challenge occur nonetheless. In response to injury,
infection, or tissue dysfunction, the CNS is capable of mounting an appropriate response
involving either the innate or adaptive immune elements discussed previously. In addition
to recruiting cells from the peripheral immune system, the CNS has its own resident
immunological cells and immune signaling pathways. In fact, the human nervous system
has a greater range of distinct cell types than any other organ system ih the body.
Although cell types are different in the CNS, they perform similar functions. Review of
the major glial cell types and their immunological roles provides a basis of comparison
between inflammation exhibited systemically versus that seen in the CNS.
The term glia originates from the Greek word meaning "glue," as nineteenth
century scientists assumed that these cells held the nervous system together. While there
is no evidence to support that glial cells bind neurons, they do serve several significant
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functions in the developing and adult eNS. They support neurons, provide the brain with
structure, produce myelin to insulate nerve cell axons, scavenge for debris following
neuronal injury or infection, guide neuronal migration and direct process outgrowth,
regulate the properties of the pre-synaptic terminal, and control neuronal metabolism by
regulating the substances that reach neurons and supplying the necessary metabolites to
axons. Glial cells can be divided into two major classes: microglia and macroglia.
Microglia are physiologically and embryologically unrelated to other eNS cell types.
Derived from mesencyme, they invade the brain in perinatal stages of development or
following brain injury in adulthood. Thus it is not surprising that microglia function as
phagocytes that respond to injury, infection and disease in the eNS. There are two types
of macroglial cells in the eNS: oligodendrocytes and astrocytes. These cells arise from
ectoderm during embryologic development. In white matter, oligodendrocytes envelop
several axonal internodes simultaneously, thus insulating these neuronal processes and
modulating the rate of nerve signal propagation. In gray matter, oligodendrocytes
surround and support neuronal cell bodies. Astrocytes are the most numerous of the glial
cells,

named for their star-shaped morphology.

Although they

have several

immunological functions, astrocytes are best known for their constitutive role as an
element of the BBB. Recent research regarding glial cell dysfunction reveals a common
mechanism implicated in the etiology of neurodegenerative and neurodevelopmental
disease.
Microglial cells are considered the resident macrophages of the eNS, as they are
the primary effector cells that respond to changes in the microenvironment and the
principle mediators of inflammation. As the first line of defense against neural infection,
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microglial cells are responsible for the innate immune response in the brain. Because of
their function in general maintenance, phagocytosis of cellular debris, and expression of
toll-like receptors (TLRs), which are types of PRRs that recognize the presence of
pathogens in their local environment, microglial cells are easily relatable to the
macrophages and dendritic cells seen systemically (Beyer et aI., 2000). They differ,
however, in that they have lower expression of various cell surface markers, which makes
them less effective at recognizing antigens or executing phagocytosis (Davoust et aI.,
2008). In healthy brain tissue, microglia are considered to be in a resting state with a
small cell soma and elaborate branching processes that extend and retract as they monitor
an area approximately

30-50~m

wide (Raivich, 2005). The motility of microglial

processes is so highly specialized that it provides them with the remarkable ability to
completely scan the neural parenchyma every few hours with little process overlap
(Nimmerjahn et aI., 2005). These microglial processes are in direct contact with
astrocytes, neurons, and blood vessels, providing the brain with a dynamic and efficient
immune surveillance system whose components are able to interact with each other.
Microglia become activated in response to brain injury or various immunological
stimulants, which induces a significant morphological change from a ramified to an
amoeboid cellular shape (Frank-Cannon et aI., 2009; Kreuzberg, 1996). This amoeboid
shape allows microglia to perform the same functions as macrophages, namely the ability
to phagocytose foreign matter, serve as APCs, produce inflammatory mediators in the
form of cytokines and chemokines, and recruit T cells to the site of injury. Damaged
tissue, infectious agents, and PAMPs are recognized by microglial PRRs, which trigger
the rapid cellular activation and release of several soluble factors that can be pro- or anti-
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inflammatory in nature and may also be cytotoxic (Liao et aI., 2004; Liu et aI., 2002; S.
C. Morgan et aI., 2004; Moss & Bates, 2001). Microglia are capable of proliferation
(microgliosis) upon activation, a condition associated with several pathological
conditions (Streit et aI., 1999). Meningeal inflammation evidenced by diffuse microglial
activation can be particularly detrimental to brain tissue, and is associated with
demyelination, substantial neuron, astrocyte and oligodendrocyte loss, and pronounced
cortical thinning (Magliozzi et aI., 2010). Conversely, research indicates that the
proinflammatory response is essential in the promotion of brain and spinal cord tissue
repair following injury, specifically in remyelination, axonal regeneration, and locomotor
recovery (Arnett et aI., 2001; Boivin et aI., 2007; Kigerl et aI., 2007). Thus it seems that
microglia can have either neurotoxic and neuroprotective roles in the inflammatory
process, depending on the type of stimulus introduced or the stage of disease progression.
If microglial activation persists, the permeability of the BBB may become compromised,

allowing increased infiltration of peripheral macrophages, which propagate the
neuroinflammatory scenario (Schmid et aI., 2009).
As the most abundant glial cell population in the CNS, astrocytes outnumber
neurons ten-fold, and they play a pivotal role in maintaining CNS homeostasis and
neuronal function (Dong & Benveniste, 2001; Pekney & Nilsson, 2005). Astrocytes
contact CNS-resident immune cells and blood vessels through their long processes, which
terminate in end-feet. They maintain an extensive network of finely branched processes
that, like microglia, occupy contiguous non-overlapping domains (Bushon et aI., 2002).
Astrocytes interact extensively with microglia, and can exert both pro- and antiinflammatory effects on them (Farina et aI., 2007; Min et aI., 2006). While some
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important functional components of their end-feet include bringing nutrients to neuronal
cells, participating in synaptic function and plasticity, and maintaining an appropriate
chemical environment for neuronal signaling, astrocytes are better known for the
influence of their perivascular end-feet. When their end-feet contact microvessels within
the eNS, astrocytes cause vessel endothelial cells to form tight junctions, which restrict
systemic access to the eNS by forming a glia limitans between brain parenchyma and the
vascular system: the BBB (Bechmann et aI., 2007). Astrocytes are also highly permeable
to potassium and maintain the extracellular potassium ion concentration between
neurons. These functions protect neurons from excess firing that could interfere with cell
signaling. In addition to maintaining the integrity of the BBB and protecting neurons
from surfeit potassium influx, astrocytes detoxify excess excitatory amino acids,
metabolize neurotrophic factors, and secrete proinflammatory cytokines and chemokines
(Bauer et aI., 2001; Nedergaard et aI., 2002; Prat et aI., 2001). Like microglial cells,
astrocytes express basal levels of TLRs, where TLR3 is most predominantly expressed
(Bsibsi et aI., 2006; Farina et aI., 2005). Importantly, astrocytes interact with and
modulate the actions of other cell types such as microglia and monocytes, and even
down-regulate their activation (Andjelkovic et aI., 2000; Kostianovsky et aI., 2008).
Like

microglia,

astrocytes

are

also

responsible

for

propagating

the

neuroinflammatory scenerio. There is evidence that in addition to forming the BBB,
astrocytes up-regUlate many BBB features in response to particular exposures within their
microenvironment (Haseloff et aI., 2005; Hayashi et aI., 1997; Sobue et aI., 1999). This
process can have detrimental ramifications.

Several eNS

pathologies involve

disturbances of BBB function and astrocyte-endothelial cooperation including stroke,
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bacterial infection, multiple sclerosis, HIV, Alzheimer's disease, Parkinson's disease,
epilepsy, and brain tumors (Abbott et aI., 2006). Reactive astrogliosis occurs in response
to infection, trauma, ischemia, and neurodegenerative disease, which causes molecular
and morphologic changes in astrocytes, and may also cause scar formation (Eddleston &
Mucke, 1993; Maragakis & Rothstein, 2006; Pekney & Nilsson, 2005). Glial scar
formation occurs in response to extreme tissue damage and inflammation when astrocyte
proliferation and processes overlap to form barriers that prevent axon regeneration and
inflammatory cell infiltration in an effort to protect healthy tissue (Bush et aI., 1999;
Herrmann et aI., 2008). In this way, glial scars can be neuroprotective by forming potent
cell migration barriers that separate areas of intense inflammation from healthy tissue,
and prevent the infiltration of inflammatory cells or infectious agents (Sofroniew, 2005).
Recent research indicates that astrocytes enhance neutrophil survival and regulate
neutrophil function, a process that may be considered neuroprotective since necrotic
neutrophils are neurotoxic and enhancing their phagocytotic abilities is protective against
microbial infection (Xie et aI., 2010). It is becoming increasingly clear that different
specific signaling mechanisms trigger different functional changes in reactive astrocytes
in a context-dependent manner, which can impact neural function, regulation of blood
flow, synaptic function and plasticity (Sofroniew, 2009).
Resident oligodendrocytes and neuronal cells are also capable of participating in
the innate immune response of the CNS. Cellular apoptosis, necrosis, and inflammation
are associated with white-matter damage in response to CNS injury (Raghupathi, 2004).
Pericytes, perivascular macrophages and neurons have been shown to contribute to BBB
induction (Ramsauer et aI., 2002; Schiera et aI., 2003; Zenker et aI., 2003). In addition to
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microglial cells, other types of CNS macrophages exist of mesodermal origin, including
perivascular, meningeal, and chroid plexus macrophages. Recent studies have found that,
like astrocytes and microglial cells, perivascular and chroid plexus macrophages also
express TLRs (Crack & Bray, 2007; Laflamme & Rivest, 2001). There is ample evidence
to suggest that almost all CNS cell types participate in the pathophysiology of CNS
trauma and immune activation as a byproduct of being a component in a complex neural
network that can have both beneficial and detrimental effects depending on
environmental context. No doubt the discovery of new neuroimmunomodulatory
mechanisms will continue to evolve the neuroinflammatory paradigm.
Resident CNS immune cells share many similarities with systemic immune cells,
in that they express various PRRs, communicate using the same chemical mediators such
as cytokines, and modulate inflammatory behavior through a complex cellular network.
Embryologically, most neuroimmune cells are derived from different tissue than systemic
immune cells, with the exception of microglia. Although these cells are physiologically
different, they perform similar functions as their systemic counterparts. Acute
neuroinflammatory responses, like systemic ones, are usually short-lived and considered
beneficial to the CNS because they repair damaged tissue and prevent further injury.
Chronic neuroinflammation, however, is detrimental and damaging to the nervous
system. It is characterized by long term activation of microglial cells, increased
expreSSIOn of inflammatory mediators, and increased oxidative and nitrosative stress
(Tansey et aI., 2007). Chronic neuroinflammation has been implicated in the etiology of
various neurodegenerative disorders, including multiple sclerosis, Alzheimer's disease,
Parkinson's disease, and Huntington's disease (Block & Hong, 2005; E. G. McGeer &
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McGeer, 2007). Here, it is proposed that neuroinflammatory processes playa role in the
etiology and pathophysiology of ASD.

Cytokine Polymorphisms: Implications in CNS Disease
Cytokines are a diverse group of soluble regulatory proteins that function as
mediators in many physiological processes, including inflammation, immunity and
hemopoiesis. As mediators, cytokines regulate the migration, activation, proliferation,
differentiation, and function of the many types of cells involved in inflammatory and
immune responses. While they are essential to maintaining protective immunity,
cytokines have been implicated in autoimmune diseases and diseases with a chronic
inflammatory component (Borish & Steinke, 2003).
Cytokines are usually very complex in their activities. Most cytokines are highly
pleiotropic and act on many different cell types exerting different effects. Different
cytokines can have redundant effects, or their activities can be either synergistic or
antagonistic depending on the target cells. Normally, cytokines do not act alone, but are
produced in a cascade fashion, and it is their combined effect that determines the type of
response. The responsiveness of a cell to a particular cytokine is determined by the
expression of specific receptors for that cytokine. The binding of the cytokine to its
receptor then triggers the activation of a variety of signaling mechanisms that lead to
changes in at the level of gene expression, resulting in transient-or chronic-altered
cellular proliferation, differentiation, and/or function.
Cytokines play an essential role in the regulation of inflammatory responses and
are involved in the regulation of both innate and acquired immunities. The cytokines that
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function in innate immunity and inflammation are normally produced by cells of the
monocitic and myeloid lineages and several other types of cells in response to microbial,
chemical, physical, and other types of inflammatory stimuli. The main goal of cytokines
in these responses is the localization and elimination of the instigating insult,
orchestrating the recruitment of both cells and molecules (accomplished through
increased vascular permeability and leukocyte infiltration) at the local site and a variety
of systemic responses that include fever, acute-phase protein synthesis and the
mobilization of leukocytes from the bone marrow. Among the main cytokines involved in
these responses are tumor necrosis factor a (TNFa), interleukin (IL)-l, IL-6, IL-12, type
I interferons (IFN; IFNa and

IFN~),

and chemokines, a family of cytokines that function

to mobilize and attract different types of leukocytes to sites of inflammation. These
cytokines are said to have pro inflammatory activity. If cytokines are secreted in excess as
a result of an overwhelming infection, or in cases where the insult cannot be easily
eliminated or the stimulus for cytokine secretion persists, leading to chronic
inflammation, these same cytokines can have pathologic effects leading to the damage of
healthy cells and tissues. Because of its potentially serious consequences, the immune
system has mechanisms to prevent excessive inflammation, including cytokines with
anti-inflammatory activity. These cytokines include transforming growth factor

~ (TGF~)

and IL-lO, which antagonize many of the effects of the proinflammatory cytokines
mentioned above. It should be kept in mind, however, that certain cytokines can have
both pro- and anti-inflammatory effects depending on different factors such as the cell
and tissue type and the kinetics of release.
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In acquired immunity, cytokines play an equally important role. In general, the

type of cytokines produced during an immune response determines the effector
mechanisms that predominate and major expression patterns have been characterized
(Mosmann & Coffman, 1989). For example, different subsets of helper (CD4+) T cells
that differ in both their cytokine secretion patterns and the effector mechanisms that they
induce have been identified. Cells belonging to the Thl subset secrete IFNy, IL-2 and
TNF

aJ~

and are primarily involved in cellular immunity mechanisms and delayed-type

hypersensitivity reactions; cells of the Th2 subset secrete IL-4, IL-5, IL-I0 and IL-13 and
are primarily involved in humoral mechanisms and allergic-type reactions; and cells of
the newly described Th17 subset secrete IL-17, IL-22 and a variety of other
proinflammatory cytokines (Harrington et a!., 2006). Th17 cells are thought to be
involved not only in immune responses to extracellular bacteria but also in autoimmune
diseases. Thl and Th2 cells affect one another: Thl cells trigger macrophage activation
using IFNy, which inhibits the proliferation of Th2 cells, and Th2 cells secrete IL-IO,
which inhibits the secretion of IFNy by Th 1 cells. In keeping with the need for balance in
the immune system, a different subset of T cells exists, namely T -regulatory cells, which
act as negative regulators of the activities of other subsets. These cells act, in part,
through the secretion of the anti-inflammatory cytokines

TGF~

and IL-IO (Bettelli et a!.,

2006).
Both in innate and acquired immunity, the maintenance of a balance between proand anti-inflammatory cytokines or among the different CD4+ T-cell subsets and their
cytokines is essential for homeostasis and the proper function of the immune system.
Disruptions in the balance can have pathologic implications resulting in excessive
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inflammation and tissue damage, increased susceptibility to infectious agents, and/or the
emergence of autoimmune conditions (Ollier, 2004). Abnormal levels of various
cytokines have been described in many diseases, such as autoimmune hepatitis,
rheumatoid arthritis, asthma, systemic lupus erythematosus, inflammatory bowel disease,
and some brain disorders like schizophrenia and Alzheimer's disease (Kronfol & Remick,
2000; Theoharides et aI., 2004; Vitkovic et aI., 2000). Given that cytokines are key
components in the homeostatic mechanisms regulating the immune system, it is not
surprising that variations

III

their structure at the genetic or protein level or their

production level have been associated with disease processes and the susceptibility to
infections.
Cytokines and their receptors are encoded by highly polymorphic genes. These
polymorphisms are responsible for the observed inter-individual differences in cytokine
production and they likely impact the immune response (Hollegaard & Bidwell, 2006;
Keen, 2002b; Wade et aI., 2003). Cytokine genes and their receptor genes are highly
conserved in their exon sequences, while the majority of polymorphisms occur in the
non-translated regions of the gene, located within the promoter, the introns, or the
untranslated-3' regions (Keen, 2002a). Cytokine polymorphisms continue to be
discovered as mutation detection techniques improve to map the extent of cytokine
polymorphisms. Cytokines that were once thought to be non-polymorphic, such as IL-2,
IL-8, and IL-12 are now being shown to have single nucleotide pol ymorphisms (SNPs),
often within the 5' promoter regions (Keen, 2002b). Polymorphisms that occur in
promoter regions impact the levels of protein expression in several ways. Polymorphisms
within the 3' and 5' regulatory sequences can affect transcription factors. Intronic
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polymorphisms can affect mRNA splicing or the binding of enhancers and silencers
(Keen, 2002b).

As the amount of data on cytokine polymorphisms increases and

becomes available, there are a growing number of studies that show an effect of cytokine
gene polymorphism on immune disease susceptibility, severity, and outcome (Keen,
2002a).
Most cytokines can be synthesized and released within the central nervous
system and while they are mainly produced by microglia and astroglia, neurons also
produce cytokines under certain conditions. Although cytokines are usually secreted in
response to specific stimuli, the low-level expression of specific cytokines appears to be
maintained in blood vessels within the brain (Licinio et aI., 1998; Vitkovic et aI., 2000).
Within the eNS, just as within the systemic immune system, cytokines are regulated in
cascades through feedback loops, and cytokine receptors have been detected in the brain
(Kronfol & Remick, 2000). Besides providing communication between neural cells,
specific cytokines have a significant role in signaling the brain to produce neurochemical,
neuroendocrine, neuroimmune, and behavioral changes (Maes et aI., 1995). There is
suggestive evidence that this signaling is part of the comprehensive mechanism to
mobilize resources to combat physical and physiological stress in an attempt to maintain
relative homeostasis. Because cytokines are associated with central neurotransmitters and
cytokine regulation is affected by stress, many studies have investigated the possible role
of cytokines in psychiatric disorders. These studies have demonstrated the role of
abnormal levels of cytokines in major depression, Alzheimer's disease and schizophrenia
(Hanson & Gottesman, 2005; Hopkins, 2007; Maes et aI., 1995; P. McGeer & McGeer,
2001a, 2001b). Analysis of cytokine genetics in autism, however, is yet uninvestigated.
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Evidence for Systemic Immune Dysfunction in ASD
In addition to behavioral and neurological impairments, increasing evidence
substantiates that immune abnormalities are also prevalent in patients diagnosed with
ASD. Epidemiological studies demonstrate that ASD is strongly associated with various
familial autoimmune diseases. Mothers and relatives of autistic patients are significantly
more likely to have autoimmune diseases such as multiple sclerosis, rheumatoid arthritis,
and type 2 diabetes, than are family members of healthy controls (Comi et aI., 1999).
Interestingly, it has also been shown that the frequency of autoimmune diseases including
hypothyroidism and rheumatic fever is significantly increased in families that have a
child diagnosed with ASD in comparison with families that have a child with an
autoimmune disorder (Sweeten et aI., 2003a). A medical record study found that mothers
who suffer from asthma or allergies during their second trimester are at the highest risk of
having a child with ASD (Croen et aI., 2005). A recent Danish study indicated that
parental autoimmune conditions, specifically maternal ulcerative colitis and paternal type
1 diabetes, are significantly associated with the incidence of infantile autism (Mouridsen

et aI., 2007). While there is no definitive autoantibody pattern in ASD, enhanced
autoimmunity has been reported in several cases, leading some investigators to speculate
whether autism should be considered an autoimmune disease (Ashwood & Van de Water,
2004).
Several systemic immune aberrations have been demonstrated in patients with
ASD, lending further support to the hypothesis that immune factors play a role in its
pathogenesis. Changes in the numbers and activities of various immune cells indicate that
both cell-mediated and humoral immunity are impaired in ASD. Autistic children
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demonstrate significantly higher monocyte counts in blood plasma when compared to
healthy controls, suggesting that their immune system is activated (Sweeten et aI.,
2003b). It has been reported that 45% of children with autism have significantly
decreased NK cell activity compared to controls, indicating that the innate immune
system's ability to kill virus-infected or damaged cells is diminished (Vojdani et aI.,
2008). Significantly increased serum concentrations of albumin, gamma globulin, and
immunoglobulins of the IgG subclass have been reported in children with autism,
suggesting an enhanced susceptibility to viral infection (Croonenberghs et aI., 2002b).
Upon stimulation with various agents, peripheral blood mononuclear cells (PBMC) of
ASD patients produce significantly higher amounts of proinflammatory cytokines than
controls, yet another demonstration of aberrant innate immune responses associated with
the disorder (Jyonouchi et aI., 2001). Plasma levels of active

TGF-~1

are significantly

lower in ASD children when compared to both typically developing children and children
with developmental disabilities, suggesting that immune responses in autism may, in part,
be regulated by this cytokine (Ashwood et aI., 2008).
Anomalous T cell function and numbers have been reported in autism, but
specific findings have not been reproducible. Adaptive immune responses stimulated by
exposure to specific antigens are often driven by T helper (Th) cells, which are classified
into two or more distinct functional types based on the cytokines that they produce and
which ultimately determine their effector functions (Abbas et aI., 1996). Among these,
Th1 cells are stimulated mainly by intracellular pathogens and promote the activation and
microbicidal activities of phagocytes by producing cytokines such as IFN-y. Th2 cells are
stimulated by chronic parasitic infections or allergens, and promote the production of IgE
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antibodies by B cells and the activation of eosinophils by producing cytokines such as IL4 and IL-S. Elevated levels of both Thl and Th2 cytokines have been reported in children
with ASD, which suggest that an imbalance of Thl or Th2 cytokines may playa role in
its pathogenesis. Evidence of Th system shifts from Thl to increased Th2 activity is
supported by decreases in intracellular IL-2 and IFN-y production and increases in IL-4
production (Gupta et aI., 1998). A study of PBMC in children with ASD found that they
produced significantly higher levels of the Th2 cytokines IL-4, IL-S and IL-13 than
controls at baseline, suggesting that the immune response appears to be predominantly
Th2 in origin (Molloy et aI., 2006). However, other investigators have found significantly
elevated plasma production of IL,-2, IL-12 and IFN-y, suggesting that autism involves
activation of the Thl type of immune response (Singh, 1996). Studies of whole blood
cultures from children with ASD have also shown increased levels of IFN-y production,
supporting a Thl response (Croonenberghs et aI., 2002a). These preliminary findings
have not been replicated in subsequent studies perhaps due to differences in
methodology, ASD classification criteria, co-morbidity presence, case-control matching
criteria, immunization status, or co-administration of psychotropic medications.
Although the evidence is controversial, gastrointestinal symptoms and an
inflammatory mucosal pathology have been demonstrated in a subset of children with
ASD as well (Horvath et aI., 1999; Wakefield et aI., 2000). While prevalence estimates
from population-based studies are lacking, epidemiological studies report that
approximately 20% of ASD children have GI symptoms (Fombonne et aI., 2001; Taylor
et aI., 2002). Intestinal pathologies include ileo-colic lymphoid nodular hyperplasia,
enterocolitis, gastritis and esophagitis (Furlano et aI., 2001; Torrente et aI., 2002;
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Wakefield et aI., 2000l Gluten and casein-free diets have proven to improve behavior in
ASD children (Knivesberg et aI., 2002). There is evidence that a dysregulated
proinflammatory cytokine profile and reduced level of regulatory cytokines is present in
the peripheral blood and intestinal mucosa of children with ASD who have
gastrointestinal symptoms (Ashwood & Wakefield, 2006). This data suggests that ASD
pathogenesis may result from a primary mucosal immunopathology during development
that leads to the secondary systemic and eNS immunopathologies seen in these patients.
How the immune dysfunctions seen in ASD are related to the neuropathies that
typify this disorder is not yet understood, but it may have significant implications
regarding disease pathogenesis and treatment. The apparent association between ASD
diagnosis and familial autoimmune disease prevalence suggests that common genes
and/or environmental factors may contribute to both immune dysfunction and
developmental brain pathologies. Immune responses measured in children with ASD
have yielded contradictory results, and these studies suffer from inherent limitations. An
estimated 46% of children with ASD are treated with psychotropic medications that are
known to increase cytokine levels, which could serve as a significant confounding factor
in the baseline measurements of these immune mediators (Aman et aI., 2003; Haack et
aI., 1999; Pollmacher et aI., 2000). Additionally, the developmental progression with
regards to the immune system is unclear since no longitudinal studies have been
performed, thus it is not known how the cytokine responses of ASD children change over
time compared to neurotypical children. Further investigations into the immune

Due to issues pertaining to patient collection bias and possible conflicts of interest
regarding data interpretation, the majority of the authors on the Wakefield et al., 2000
paper retracted this article from public record in January 2010.
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regulatory mechanisms in ASD are clearly warranted, and will likely yield therapeutic
applications.

Evidence for CNS Immune Dysfunction in ASD
Increasing evidence indicates that in addition to systemic immune abnormalities,
an atypical CNS immune profile is also present in ASD patients. Autistic patients have
significantly higher levels of circulating anti-brain autoantibodies when compared to
controls; including antibodies to myelin basic protein, cerebellar neurofillaments, neuronaxon filament proteins, caudate nucleus, serotonin receptor, and brain endothelial cells
(Connolloy et aI., 1999; Plioplys et aI., 1989; Singh & Rivas, 2004; Singh et aI., 1997a;
Singh et aI., 1997b; Singh et aI., 1993). It has also been shown that glial fibrillary acidic
protein is significantly elevated in the CSF of children with ASD, which indicates an
ongoing process of reactive astrogliosis (Rosengren et aI., 1992). Whether or not the
presence of anti-brain antibodies and reactive astrogliosis are primary or secondary
factors in the pathophysiology of ASD is yet to be determined, but these studies suggest
that localized inflammation of the central nervous system may be a contributing factor.
While only a few studies have been performed regarding neuroinflammation in
ASD, they demonstrate an active and ongoing neuroinflammatory process in the cerebral
cortex, white matter, and cerebellum. Immunohistochemical studies of brain tissue from
ASD patients reveal marked microglial and astroglial activation in the anterior cingulate
gyrus and midfrontal gyrus, with the most prominent activation in the granular cell layer
and white matter of the cerebellum (Vargas et aI., 2005). The dorsolateral prefrontal
cortex of autistic individuals demonstrates significant increases in white matter microglial
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somal volume and gray matter microglial density that does not correlate with age and
appears to be heterogeneous (J. T. Morgan et al., 2010). The anti-inflammatory cytokine
TGF-p 1 is significantly increased in cortical and cerebellar regions, and the largest
spectrum of increases in pro-inflammatory cytokines is present in the anterior cingulate
gyrus of autistic individuals (Vargas et al., 2005). Of particular interest from this study
are one chemokine, macrophage chemoattractant protein-l (MCP-l), and one cytokine,
TGF-p 1. MCP-l is produced by activated astrocytes, mediates the infiltration of
monocytes and macrophages to areas of injury, and its elevation in brain tissue is
associated with various diseases characterized by neuroinflammation (Henkel et al.,
2004; Kelder et al., 1998; Mahad & Ransohoff, 2003). TGF-pl is an anti-inflammatory
cytokine, with key roles in tissue remodeling and repair following injury, that suppresses
the immune response by inhibiting T-cell proliferation and maturation and downregulating the expression of MHC II receptors (Letterio & Roberts, 1998). Reactive
astrocytes were found to be the main source of cytokines in the brains of autistic subjects
(Vargas et al., 2005). Significant increases in several proinflammatory cytokines (TNF-a,
IL-6, GM-CSF, IFN-y, and IL-8) have been demonstrated in the frontal cortex of patients
with ASD when compared to controls, with no concomitant increase in the Th2 cytokines
(IL-4, IL-5 and IL-lO) analyzed (Li et al., 2009). It has been proposed that the presence
of activated neuroglia and proinflammatory cytokines in the CNS of autistic subjects may
reflect an abnormal persistence of fetal patterns of development in response to genetic
and/or environmental factors

that disturb
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neurodevelopment and produce the

neurocytoarchitectural changes and CNS dysfunction that typifies ASD

3

(Pardo &

Eberhart, 2007).
Consistent and significantly higher levels of activated immune markers have also
been measured in the CSF of ASD subjects, indicating an overall pro-inflammatory
profile. CSF from autistic patients shows a significant increase in MCP-l, IL-6, IFNyand
IL-8 when compared to controls (Vargas et aI., 2005). In a pilot study of autistic children
with developmental regression, comparative analysis of CSF to concurrent cytokine
serum levels in autistic patients demonstrates a significant elevation of TNF-a expression
in CSF, with an averaged ratio of 53: 1 compared to a 1: 1 ratio for control subjects (Chez
et aI., 2007). These results suggest that TNF-a in CSF may serve as a potential marker
for the pathological process involved in autistic regression. Evidence indicates that levels
of soluble tumor necrosis factor receptor II are significantly elevated in the CSF of
children with autism, which do not reflect serum expression levels in the same
individuals either (Zimmerman et aI., 2005). While CSF studies of immune mediators in
autism are still in their infancy, these findings can be interpreted as indicators of chronic
neuroinflammation.
In order to better understand the molecular changes associated with ASD
neuropathology, investigators have assessed the immune transcriptome in the cerebral

3 A cautionary note in reference to immunocytochemical studies of postmortem brain
tissue from autistic subjects: a majority of the patients studied in the Vargas et aI., 2005,
Li et aI., 2009, and Morgan et aI., 2010 died of hypoxic lesions that were ischemic in
origin including near death experiences associated with drowning. Ischemic reperfusion
injuries of this kind result in inflammation and oxidative damage primarily targeting
white matter, and are defined neuropathologic ally by astrogliosis and micro gliosis.
Therefore, it cannot be determined whether the neuroinflammation present in these
tissues represents a core pathology associated with ASD or are secondary reactions of
this tissue associated with the cause of death.
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cortex of postmortem brain specimens. Expression profiling of the superior temporal
gyrus reveals that transcriptome variability is generally increased in autistic subjects,
indicating that the disorder is heterogeneous even at the molecular level (Garbett et aI.,
2008). Cytokine and chemokine transcriptional analysis in various cortical regions
reveals a heterogeneous regulation of expression of these proteins when compared to
controls (Mott et aI., unpublished data). Given that cytokines mediate inflammatory
responses in the CNS and that their heterogeneous expression in cortical tissue is
associated with ASD pathology, comparative analysis of polymorphic sites in cytokine
genes may produce significant results and implicate them in the pathogenesis of this
neurodevelopmental disorder.
Given the abovementioned neurOlmmune evidence and the neuropathological
features that typify this disorder, it has been proposed that a critical period of
pathogenesis occurs during fetal brain development or in the first year of life which
results in the ASD phenotype (Pardo, 2008; Pardo & Eberhart, 2007). The dominant
features of ASD neuropathology include abnormalities in mini-columnar organization
and subcortical white matter, disorganization of cortical neurons, and brain growth
abnormalities (Bauman & Kemper, 2005; Casanova, 2007). The neurobiological and
behavioral features that characterize ASD could be attributed to a pathogenic process that
disturbs neurodevelopment during crucial periods pre- or perinatally. Recent studies
show that maternal autoantibodies are present in the serum of mothers of patients with
autism, indicating that maternal immunological factors may also play a role in the
pathogenesis of ASD (Braunschweig et aI., 2007; Singer et aI., 2008; Zimmerman et aI.,
2007). Glial neuroimmune responses are associated with pathogenic mechanisms of
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neurodegeneration in several neurological disorders, and appear to be involved in
processes that lead to neuronal dysfunction. In the future, microglial activation, reactive
astrogliosis and increased expression of specific cytokines in the CNS may provide early
markers for ASD and allow clinical diagnosis within the first year of life, even before
obvious clinical features manifest. In the meantime, immune studies in autism should
focus on elucidating the underlying neuroimmunopathology responsible for the chronic
neuroinflammation that seems to characterize at least a subset of subjects with ASD.

Etiological Evidence in an Idiopathic Disorder
Although there is no known cause of ASD, unequivocal evidence indicates that
there is a strong genetic component. Several genetic disorders are consistently associated
with autism, including Angelman syndrome, Rett's syndrome, tuberous sclerosis, fragile
X syndrome, and Down syndrome (D. Cohen et aI., 2005; Harris et aI., 2008; Lowenthal
et aI., 2007). Whether autism and these syndromes share underlying pathophysiological
genetic networks has yet to be determined, but current research in this area is underway.
Twin and family studies demonstrate that autism is one of the most highly heritable
complex neuropsychiatric conditions. In the late 1960s it was noted that the recurrence
rate of autism in a given family was 50-100 times greater than that expected by chance
(Rutter, 1968). A more recent study estimated that parents of a child diagnosed with ASD
are 25 times more likely to produce affected siblings compared to controls (L. B. Lord et
aI., 1991). While it is difficult to interpret recurrence rates of autism due to the
phenomenon of genetic 'stoppage' wherein families choose not to have more children
once an ASD diagnosis is obtained, studies report significantly higher sibling recurrence
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rates in ASD families compared to the general population (Rutter et aI., 1999; Slager et
aI., 2001). Additionally, siblings and parents of ASD patients are more likely than
controls to show cognitive and behavioral features reminiscent of those seen in the
broader autism phenotype (Bishop et aI., 2004; Bolton et aI., 1994; Costantino et aI.,
2006). These findings indicate that ASD traits are not only genetically transmitted, but
also highly heritable.
A verage concordance rates of autism

III

monozygotic (MZ) twin pans are

consistently and significantly higher than those found in dizygotic (DZ) twin pairs
(Bailey et aI., 1995; S. Folstein & Rutter, 1977; Le Couteur et aI., 1996; Lichtenstein et
aI., 2010; Ritvo et aI., 1985; Rosenberg et aI., 2009; Steffenburg et aI., 1989). Recent
research estimates average concordance rates of autism in MZ twin pairs to be 70-80%
while DZ twin pair rates are 0-10% (S. E. Folstein & Rosen-Sheidley, 2001). Even
studies investigating concordance rates in more generalized ASDs report significantly
higher MZ concordances compared to those for DZ twins (Lichtenstein et aI., 2010;
Rosenberg et aI., 2009; Taniai et aI., 2008). While some investigators postulated that
twining could be a risk factor in the development of ASD, subsequent studies do not
support this hypothesis (Betancur et aI., 2002; Croen et aI., 2002; Hallmayer et aI., 2002).
Multivariate twin studies suggest that the three core behavioral symptoms of the autism
'triad' are fractionable and highly heritable individually, such that different autistic
aspects of behavior may have distinct genetic origins (Happe & Ronald, 2008; Happe et
aI., 2006; Ronald & Hoekstra, 2011). The question of whether genetic influences can be
ascertained in a disorder defined by symptomatic heterogeneity is substantial, and
represents a significant limitation in cross-study comparison. Future research will likely
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reveal that different genetic causal pathways result

In

different ASD sUbtypes and

symptoms.
Little is known about the genes underlying autism susceptibility, and the majority
of studies focus on linkage analysis and candidate gene identification. It has been
estimated that genetic abnormalities account for up to 20% of ASDs, and include
chromosomal abnormalities, copy number variations (CNVs), single-gene disorders, and
rare point mutations (Abrahams & Geschwind, 2008; Marshall et aI., 2008). Examples of
chromosomal abnormalities identified in ASD include autosomal aneuploidies, sex
chromosome anomalies, deletions, duplications, translocations, inversions and marker
chromosomes (c. Gillberg, 1998). One of the most common sites for chromosomal
abnormalities in autism is located on chromosome 15q 11-13, where duplications of
maternal origin are frequent (S. E. Folstein & Rosen-Sheidley, 2001). The most
consistent evidence for linkage, however, occurs on chromosome 7q22-32, according to
meta-analysis (Trikalinos et aI., 2006). Other studies also implicate autism loci on
chromosome 7, as well as chromosomes 3, 4, and 11 (Schellenberg et aI., 2006). Despite
the significantly different sex ratio present in autism, few studies suggest linkage on the
X chromosome (Auranen et aI., 2002; Shao et aI., 2002). It has been proposed that

linkage analyses have yielded inconsistent findings due to limitations inherent to this
analytic approach in a complex genetic model where it is likely that multiple risk alleles
confer susceptibility to the disorder (Losh et aI., 2008).
Conversely, genome wide association scans (GWAS) and screening for CNVs
provide a more powerful approach in comparing genetic risk factors between cases and
controls in disorders of complex etiologic origin. This analytic approach is capable of
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scanning thousands of samples and applies algorithms that compare the frequencies of
single alleles or multimarker haplotypes between disease and control cohorts. Inherited
CNV s have been found in 50% of ASD subjects, as compared to control estimates of 510% (ltsara et aI., 2009; Zhao et aI., 2007). CNVs may include insertions, deletions, and
duplications of DNA, as measured in oligonucleotides and single nucleotide
polymorphisms (SNPs). While a unified genetic theory for ASD based on the observed
high frequencies of CNVs fits the prevalence estimates previously discussed, it does not
explain the sex-dependent penetrance in which males are four times more likely to be
affected (W. T. Brown, 2010; Zhao et aI., 2007). GWAS have identified several genes
and SNPs that are associated with autism disorder on chromosomes 2, 6, 7, 15, and 17;
although subsequent studies have been unable to replicate many of these findings
(Freitag, 2007).
Discordant findings in GW AS are likely due to many the same confounding
factors that make comparison between epidemiological studies in ASD difficult. Many of
the original GW AS studies had small sample sizes and thus may not be considered
reliable in detecting true autism loci. Additionally, false-positive signals are always a
possibility even in studies with large sample sizes. Perhaps the largest contributing
factors are disparities in diagnostic definition or pedigree ascertainment between studies.
Even cohorts that use similar diagnostic criteria may have somewhat different
characteristics. Examples include gender composition, language, developmental
regression, IQ distribution, family size, and ethnic origins. Future GW AS studies of large
sample size that follow rigorous diagnostic protocols and replicate distributions of cohort
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characteristics will minimize heterogeneity and provide the most accurate linkage
analysis.
Like most neuropsychiatric disorders, ASD is a syndrome of complex genetic
origin. The genetic traits that have been characterized do not exhibit classic Mendelian
dominant or recessive modes of inheritance associated with a single gene locus.
Likewise, the wide phenotypic variability found in ASD cannot be attributed to simple
modes of inheritance. Contemporary etiologic theory proposes a genetic model in which
multiple genes interact with one another to produce the autism phenotype. Thus, ASD
may be considered a polygenetic disorder whereby several genes act synergistically.
Early studies supported a multi-locus model of inheritance, where at least three epistatic
(interacting) loci were predicted (Pickles et aI., 1995). More recent estimations based on
GW AS predict as many as 10-20 different genes interact in ASD pathogenesis (Risch et
aI., 1999; Spence, 2004). GWAS and cytogenetic analyses serve to narrow down genetic
regions of interest, but they are not hypothesis-driven and do not account for clinical and
empirical evidence, which is essential in elucidating candidate genes that may predispose
individuals to disease. While it is apparent that genes strongly impact the likelihood of
developing ASD, no definitive genetic pattern has been identified although a multitude of
candidate genes have been implicated (Muhle et aI., 2004). Replications of these findings
have been inconsistent, however, likely due to the heterogeneity of the ASD phenotypes
in vestigated.
Given the neuropathological features and immunological dysfunctions that are
found in ASD subjects, genes that are known to affect neurodevelopment and immune
function are prime candidates for analysis. Several studies have linked autism with
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immune-based genes (Lee et aI., 2006; Torres et aI., 2006; Warren et aI., 1996; Warren et
aI., 1992). One group found a genetic linkage with autism for a variant of the MET
receptor tyrosine kinase, which is involved in both neurobehavioral and immune function
(Campbell et aI., 2006). It is possible that the convergence of multiple combinations of
genotypes may result in different ASD phenotypes, further complicating analytic
interpretations. Thus, the phenotypic traits of chosen cohorts must be clearly and
narrowly described when investigating candidate genes of interest. While the interaction
of multiple genetic factors has become increasingly evident as a causative function in
ASD pathogenesis, genetic influence cannot explain the increased prevalence indicated
by epidemiological studies.
Given that the autism heritability estimate is approximately 80% based on the
abovementioned twin studies, environmental factors must represent another etiologic
component in ASD pathogenesis. It has been proposed that MZ twin discordances can be
attributed to epigenetic changes, somatic mutations or chorionic environmental influences
(Bohm & Stewart, 2009; Bruder et aI., 2008; Cheung et al., 2008; Kaminsky et aI., 2009).
Two of the most salient environmental factors associated with ASD are prenatal maternal
exposures and postnatal birth complications. Perinatal obstetric complications represent a
putative risk factor for the development of ASD (Kolevzon et aI., 2007; Ronald et aI.,
2010). Types of obstetric complications associated with autism include prematurity, low
birth weight, respiratory distress syndrome, rhesus incompatibility, resuscitation,
infection, anemia, and trauma (Bolton et aI., 1997). Maternal use of various agents,
including thalidomide, valproic acid, misoprostol, and ethanol have been associated with
ASD (Aronson et aI., 1997; Bandim et aI., 2003; Christianson et aI., 1994; Moore et al.,
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2000; Nanson, 1992; Stromland et aI., 1994; G. Williams et aI., 2001). Congenital
conditions associated with autism include hypothyroidism, cytomegalovirus infection,
and rubella infection (Chess, 1971; Rovet & Ehrlich, 2000; Stubbs et aI., 1984). Although
the measles-mumps-rubella (MMR) vaccine received considerable attention in its relation
to the development of ASD, subsequent studies refute any evidence to substantiate that
MMR vaccination is a risk factor for ASD development (Dales et aI., 2001; Kaye et aI.,
2001; Madsen et aI., 2002; Taylor et aI., 1999).
Intrauterine and perinatal exposure to infectious agents and immune factors have
been implicated as primary mediators of CNS damage in several neuropsychiatric
conditions including schizophrenia, bipolar disorder, cerebral palsy and autism (Miller et
aI., 2005; Nelson et aI., 1998; Rodier & Hyman, 1998; Yolken & Torrey, 1995). It has
been proposed that ASD pathogenesis may be attributed to environmental toxicity
experienced during fetal development or early postnatal life (Deth & Muratore, 2010;
Palmer et al., 2009; Windham et aI., 2006). Xenobiotic risk factors associated with autism
include the heavy metals mercury, lead, and cadmium, as well as arsenic, maternal
smoking, alcohol, cocaine abuse, and certain pesticides (Ashwood et aI., 2006; Kern et
aI., 2007; London, 2000; Mutter et aI., 2005). Specifically, maternal seafood ingestion
and dental amalgams could provide primary sources for in utero mercury exposure, while
mercuric or aluminum vaccine preservatives may serve as potential postnatal sources
(Deth & Muratore, 2010). Although thimerosal was considered to playa causative role in
autism development, removal of this preservative from infant vaccines in 2001 did not
result in a change in prevalence of the disorder (Schechter & Grether, 2008). Pesticides
are known to have severe neurotoxic effects, and can cross the blood-brain-barrier and
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placenta. One epidemiological study reported an association between maternal residential
proximity to areas of pesticide application during gestation and incidence of ASD
(Roberts et aI., 2007). Another found an association between ASD and the use of
household pesticides, with the strongest effect during the second trimester (HertzPicciotto et aI., 2008). Of particular interest is the fact that estrogen and progesterone
have been shown to be neuroprotective against inflammatory damage, suggesting that sex
hormonal status may be a critical mediating factor involved in xenobiotically induced
inflammatory brain damage (Kipp et aI., 2007). Gender-based differences in
developmental immunotoxicity have been evidenced in animal studies of in utero
exposure to heavy metals (Bunn et aI., 2001). These studies obviously have significant
implications regarding the gender bias in ASD and suggest that it may be linked to
specific prenatal teratogenic exposures.
Maternal infection resulting in neurological damage to the offspring in a
temporally dependent manner associated with gestational development has been proposed
in ASD (Depino, 2006; Meyer et aI., 2006). Animal models of ASD, while controversial,
report behavioral and neuropathological features reminiscent of the ASD phenotype in
humans and may be useful models of etiologic investigation. Maternal respiratory viral
infections produce autistic neuropathological and behavioral features in rodent models
(Patterson, 2002; Shi et aI., 2007). Interestingly, the same group found that a single
administration of the cytokine IL-6 during a specific period of murine gestation produced
the same 'autistic' phenotype (S. E. Smith et aI., 2007). Maternal infections have also
been shown to influence the offspring immune system. For example, stimulation of proinflammatory cytokine production in rats during pregnancy resulted in innate immune
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dysfunction in the offspring (Hodyl et aI., 2007). Early life immune insult is likely a
significant component in ASD pathogenesis, but little is known regarding the precise
developmental period(s) of immune vulnerability or the array of environmental toxins,
infections or conditions that produce observable dysfunctional outcomes.
Recent evidence indicates that prenatal stress is associated with ASD. Mothers of
children diagnosed with autism disorder report significantly more stressful life events
during their pregnancies when compared to controls (Beversdorf et aI., 2005). Prenatal
stress caused by natural disasters measured in tropical storms and hurricanes from 19801995 was significantly associated with autism prevalence, which increased in a doseresponse fashion with storm severity (Kinney et aI., 2008a). Furthermore, the results of
this study indicated that fetuses exposed during gestational months 5-6 and 8-9 had
significantly greater risk of developing ASD compared to children exposed during other
gestational periods. This group outlines multiple mechanisms by which prenatal stress
could result in the altered neurodevelopmental trajectory that typifies ASD. Examples
include neuroinflammatory effects, fetal hypoxia caused by a reduction in uterine or
placental circulation, maternal stress hormones crossing the placenta and altering the
development of the hypothalamic-pituitary-adrenal axis, complications of pregnancy
and/or delivery, and epigenetic effects on gene expression involved in the stress response
(Kinney et aI., 2008b). Prenatal stress and fetal exposure to elevations of maternal stress
hormones such as testosterone during critical periods of gestation could represent a risk
factor for ASD and explain the gender differences in prevalence (Knickmeyer & BaronCohen, 2006).
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Since the interaction between genes and environment guide development, geneenvironment interactions likely play etiologic roles in ASD pathogenesis. It has been
proposed that the majority of ASD cases are caused by the combination of environmental
factors and multiple susceptibility genes (Cederlund & Gillberg, 2004; Glasson et aI.,
2004). The actual environmental insult, considered here to be of immunologic origin,
likely precedes the first neurological sign of ASD. Possible models to explain early life
immune insult and the neuropathologic/immunologic features of ASD have been
proposed elsewhere (Dietert & Dietert, 2008). Given a particular genotype, an individual
may be genetically predisposed to developing ASD based on particular pre- or perinatal
environmental exigencies. The confluence of genetic predisposition in an epistatic
multilocus model and a second "hit" from an environmental or immunogenetic risk factor
could account for the pathogenesis and etiologic heterogeneity of ASD.
Molecular pathways critical for normal neuronal and cortical organization as well
as immune function signify the most likely influential targets in a disorder typified by
dysfunction in these areas. Specifically, the HGFIMET pathway is associated with
multifunctional roles involved in these systems, and recent evidence demonstrates a
strong association of a SNP in the promoter region of the MET gene with ASD, as well as
altered levels of mRNA in proteins associated with this pathway in the brain tissue of
affected individuals (Campbell et aI., 2007; Campbell et aI., 2006). Other genes
implicated in the ASD pathophysiology have been reviewed, and include those encoding
reelin, various neurotrophins, serotonin-related genes, GABAergic receptors, neuroligins,
SHANK3, and HOXAI (Pardo & Eberhart, 2007). These genes are associated with the
neurobiological causes of autism, but cannot account for the immunological aspects of
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the disorder. Thus the search for distinguishing genetic characteristics related to ASD and
how these interact with prenatal environmental triggers to produce the ASD phenotype
remains an avenue for continued research.
While it is evident that ASDs have a strong genetic component, they have a
complex and poorly understood pattern of inheritance, likely due to the heterogeneous
nature of the disorder. Because GW AS have failed to reveal strong genetic candidates
due to conflicting results, it is probable that multiple rare genetic variants are involved.
Future linkage analyses must aim to describe endophenotypes in ASD in order to create
more narrow behavioral and pathological profiles and thereby more homogenous and
comparable samples. Current etiologic theory predicts that the confluence of genetic
predisposition at multiple interacting sites along with the presence of prenatal
environmental risk factors represents the most feasible model of ASD pathogenesis.
During which stage of development these events are likely to occur is yet undetermined.
Studies investigating prenatal windows of vulnerability in autism contain evidence to
support environmental risk at every trimester of gestation. While one study suggested that
maternal stress factors prior to the 32nd week of gestation played significant roles in ASD
incidence, still other studies suggest second and third-trimester stress and infectious risk
factors are critical (Beversdorf et aI., 2005; Kinney et aI., 2008a; Yamashita et aI., 2003).
Determining specific periods of developmental vulnerability along with identifying the
teratogenic insults that elicit the immunologic and pathologic manifestations of the ASD
phenotype will play essential roles in future prevention of the disorder. Equally as
important will be the identification of islets of genetic susceptibility associated with
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ASD, which will have significant therapeutic implications. Once these etiological
attributes are described, true prevention and treatment can begin.

Investigating Cytokine Polymorphisms and Expression in ASD: Central Hypothesis and
Specific Aims
Current literature demonstrates abnormalities in cytokine expressIOn levels in
ASD subjects when compared to controls. Independent study results, however, are
contradictory in their findings regarding characterization of these differences (see Table 1
below). One potential reason for discrepancies between studies could be associated with
comparisons of young ASD patients with adult controls, or sample cohorts that have a
wide range of ages within patient and control groups. It has been established that
cytokine expression profiles change with age in a tissue-specific manner (Csiszar et aI.,
2003; Sack et aI., 1998). Thus, studies that do not compare age-matched cohorts when
investigating cytokine expression profiles face significant confounding factors associated
with age related changes in immune mediators. Contradictory results in different autistic
samples could also confirm the presence of different endophenotypes in ASD based on
cytokine genotypes. It is reasonable to infer that the combination of these different
genotypes may bias a characteristic immune response, constitutively affecting the
Th1ffh2ffh17 balance. In the context of an acute inflammatory episode, such a bias may
tip the balance toward a more vigorous and potentially deleterious acute-phase immune
response or induce a state of chronic inflammation.
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Table 1. Cytokine expression patterns in autistic patients compared to controls: an interstudy comparison
Cytokine

Whole
blood

Plasma

ll.,-1 P
ll.,-IRA
ll.,-2
ll.,-4

11'(1) NS(5) i (6)
NS(3)

ll.,-6
ll.,-8

11'(1) NS(3) NS(4)
i (6) NS(11)
11'(1)

ll.,-10

NS(6)

NS(3)

ll.,-12
IFN-y

11' (I) 11'(4)
11'(4) NS(5)

11'(3)

TNFa

NS(4) NS(5)

i (3)

TGFp-1

U (2) U (9)

11'(3)

i (3)

PBMC

NS(7) 11'(8)
NS(8)
NS(7) i(l4)
11'(14)
NS(7) 11'(8)

CSF

Brain

NS(I3)
i(ll)
NS(13)
11'(12)

i (12) 11'(13)
11'(13)

NS(7) U ( IO)
NS(14)
NS(7)
NS(7) i(1 4)
NS(7) 11'(8)
11'(10)

i (12) NS(13)
11'(14)

11' (13)
11'(13)
11'(12)

11' USignificantly increased/decreased level (p~ 0.05), iTrend toward increased level that
does not reach significance, NS No significant difference. PBMC: Peripheral blood
mononuclear cells, CSF: cerebrospinal fluid.
Study Index:
1. (Ashwood et ai., 2011)

8. (Jyonouchi et ai., 2001)

2. (Okada et ai., 2007)

9. (Ashwood et ai., 2008)

3. (Croonenberghs et ai. , 2002a)

10. (Ashwood & Wakefield, 2006)

4. (Singh, 1996)

11. (Zimmerman et ai., 2005)

5. (Sweeten et ai., 2004)

12. (Vargas et ai., 2005)

6. (Emanuele et ai., 2010)

13. (Li et ai., 2009)

7. (Saresella et ai., 2009)

14. (Molloy et ai., 2006)
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There is currently not enough evidence to determine if the abnormal immune
response present in ASD is a contributing factor for or a simple by-product of the disease.
However, growing evidence demonstrates that ASD may be caused by the combination
of genetic susceptibility and specific environmental insults that occur during
neurodevelopment such as particular infections or antigens in the diet; and a
pro inflammatory scenario associated with abnormal cytokine production would
exacerbate the whole process. It is possible that there are phenotypes of the immune
system predisposed to stronger or weaker inflammatory immune responses, chronic
inflammation or autoimmunity, and that these phenotypes can manifest from several
different combinations of genotypes in different cytokine genes with variable expression.
The combinations of specific genotypes of multiple cytokines may therefore be useful as
markers for specific autistic endophenotypes.
Immune activation during pregnancy can impact offspring neurodevelopment
with far-reaching behavioral sequelae. Cytokine levels are altered in human pregnancies
complicated with infection and maternally generated cytokines can cross the placenta and
enter fetal circulation (Depino, 2006; Zaretsky et ai., 2004). Thus, it is possible that a
maternal abnormal immune response linked to infection or injury during pregnancy may
be one contributing factor for altered neurological development in the fetus. The immune
activation of pregnant mice or rats using either lipopolysaccharide (a proxy for bacterial
infection) or polyriboinosinic polyribocytidylic acid (a proxy for viral infection) results in
modified cytokine expression in the maternal-fetal tandem pair (Gillmore et ai., 2005;
Urakubo et ai., 2001). Furthermore, the timing of the insult during gestation is important
with regard to the ultimate neurological and behavioral impact (S. E. Smith et ai., 2007).
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A recent study of maternal infection requiring hospitalization during pregnancy found
that first trimester viral infection and second trimester bacterial infection were
significantly associated with ASD diagnosis (Altadottir et aI., 2010). It is inferred here
that the timing and etiological origin of immune activation potentiates different
neurological and behavioral fetal results, and that variability due to cytokine expression
polymorphisms could either exacerbate or attenuate the degree of both maternal and fetal
immune activations.
If specific cytokine genotypes associated with abnormal cytokine expression are

linked to autism, this could be understood as a genetic predisposition to ASD. Given
expression polymorphisms in certain key cytokine genes, some overall immune
phenotypes will be predisposed for stronger or weaker immune activation, contributing to
the etiology or emergence of autism. Beyond the concept of cause and effect, it is
proposed here that specific genetic cytokine make up may be a risk factor that will
exacerbate any immune response triggered by multiple prenatal environmental factors
leading to the oxidative stress and neuropathological abnormalities present in this disease.
Maternal and/or fetal immune activation may permanently alter the fetal Thlffh2ffh17
balance, predisposing the fetus to a lifetime of chronic inflammatory or autoimmunity
issues.
The central hypothesis investigated herein purports that autism pathogenesis is
caused by the combination of genetic susceptibility in cytokine genes and a second "hit"
prenatal infectious scenario that occurs during specific periods of neurodevelopment. The
questions this research aims to answer are:
1.) Do cytokine genes differ between autistic subjects and controls?
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2.) Does cytokine transcriptional expressIOn differ significantly from that of
controls in the cerebral cortex of autistic patients?
3.) Can cytokine expression profiles be modified systemically in autism?
Specific experimental aims were designed to address each question, and are relayed
below.
Experimental aim 1 was to characterize different SNPs of selected candidate
genes encoding cytokines

In

autistic patients and controls. Based on prevIOus

investigations that convey abnormal expression levels of cytokines in ASD, it is
hypothesized that there will exist significant differences between cytokine SNPs in an
autism cohort compared to neurotypical controls. A positive association with ASD for
cytokine SNPs could be interpreted as genetic susceptibility and represent a significant
risk factor for ASD pathogenesis.
Experimental aim 2 was to characterize the transcription (mRNA) pattern for
chosen cytokines in postmortem cortical brain tissue of autistic patients and compare
these to control values. Previous investigations of cytokine translational (protein) profiles
have revealed significant differences in cytokine expression between autistic subjects and
controls (see Table 1). The assumption, based on molecular dogma, is that investigated
transcriptional patterns will reflect translational patterns already established. If cytokine
mRNA patterns are not significantly different between autistic and control cohorts, this
would indicate that post-transcriptional modification of cytokine genes my playa role in
ASD pathogenesis. This would open new investigative areas of etiologic research in ASD
focused on molecular mechanisms of immunogenetic regulation.
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Experimental aim 3 was to characterize the cytokine translational expression
patterns in autistic subjects treated with placebo or glutathione. Systemic oxidative stress
has been documented in autistic children (Chauhan & Chauhan, 2006; James et aI.,
2004). The tripeptide glutathione is the primary determinant of redox status in human
cells (Schafer & Buettner, 2001). Plasma levels of glutathione are abnormally decreased
in autistic subjects (James et aI., 2004). Glutathione has significant impact on a multitude
of cellular processes involved in immune signaling. It is known to modulate cell
differentiation, proliferation, antigen presentation, regulate apoptosis, and enhance
lymphocyte proliferation. Disturbances in glutathione homeostasis are implicated in the
etiology and progression of neurodegenerative diseases (Ballatori et aI., 2009). It is
proposed here that intravenous administration of glutathione in autistic subjects will alter
systemic cytokine expression and ameliorate behavioral symptoms. If cytokine
expression levels are significantly altered (and reflect expression patterns seen in
neurotypical subjects) in response to glutathione administration, this could represent a
metabolic treatment for autism with potential therapeutic applications.
The focus of this research is to determine if cytokine genetic and expressional
profiles can be linked, in a causative fashion, to the pathophysiology of ASD. Because of
their role in prenatal neurodevelopment and immune signaling pathways, cytokines offer
an associative link between the abnormal immunological profiles and neuropathological
features present in this disorder. Indications of a genetic susceptibility in cytokine genes
linked to abnormal expression profiles would provide significant etiologic evidence in
this idiopathic disease. In addition, metabolic treatment that regulates cytokine expression
may yield substantial therapeutic implications.
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CHAPTER II

Cytokine Polymorphisms in Autism

Introduction
Autism is an idiopathic neurodevelopmental disorder that typically appears during
the first three years of life. It is diagnosed on the basis of impairments in cognition, social
interaction, and communication (American Psychiatric Association, 2000). Autism
spectrum disorder (AS D) comprises a broader category of neurodevelopmental disorders
including autistic disorder, Asperger's disorder and pervasive developmental disorder not
otherwise specified (PDD-NOS). An epidemiological survey performed in 2007-2008
found that 1.1 % of children in the United States aged 3 to 17 years old are currently
diagnosed with ASD, and males are four times more likely to be diagnosed than females
(Kogan et aI., 2009). Though the etiology remains largely unclear, ASD is a highly
heritable disorder (85 %) that affects monozygotic and dizygotic twins twelve and four
times greater, respectively, than the general population (Greenberg et aI., 2001; Spence,
2004). In the largest and most recent study of proband-ascertained twin pairs, it was
found that pairwise ASD concordance was 31 % for dizygotic and 88% for monozygotic
twins; and this data also suggests that zygosity and sex may contribute to ASD
heritability (Rosenberg et aI., 2009). Family studies have shown that parents of an
affected child are more likely than control parents to demonstrate cognitive or behavioral
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features that are reminiscent of those found in ASD, though fail to achieve diagnosis
(Losh et aI., 2008).
Genome-wide association studies have rendered some relevant findings for
possible genetic risk factors, but lack consistency; that is, none of the single nucleotide
polymorphisms (SNPs) or genomic regions correlated with ASD has been replicated
across studies. This apparent lack of consistency may be due to several reasons. How
different studies clinically conceptualize ASD endophenotypes may rule out the
possibility of consistency. It has been shown that analysis of different core deficits results
in associations with multiple different regions of the genome (Schellenberg et aI., 2006).
Rare variants that impinge on common neurodevelopmental pathways may lead to
convergent diagnosis (Bucan et aI., 2009). At issue is whether ASD en do phenotypes truly
represent a spectrum of neurological behavior and deficits with a common underlying
pathology or are rather a collection of similar behaviors of heterogeneous genetic and/or
developmental origin. Association studies assume environmental homogeneity, but it is
likely that ASD is the result of combinations of variable genetic susceptibilities and
pertinent environmental exposures.
Recent studies suggest a strong immunological component may contribute to the
pathogenesis of ASD. An increased prevalence of autoimmune disorders has been
reported among first- and second-degree relatives of children with ASD when compared
to controls; even when compared to families of children with autoimmune diseases
(Sweeten et aI., 2003a). Interestingly, in detailed analysis of ASD SUbtypes in Sweeten et
aI., it was found that an increased frequency of autoimmunity existed in the autism and
Asperger's disorder families when compared to those of children with autoimmune
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diseases-but not in the PDD-NOS families. Research demonstrates that some autistic
children have perturbed cellular and humoral immunity (Gupta, 2000; Plioplys et aI.,
1994; Saresella et aI., 2009). Brain protein auto-antibodies have been found in sera from
autistic children, implying an autoimmune response is present in this disorder in the
individuals studied (Singh et aI., 2002; Singh et aI., 1998). Research from the same group
maintains that a major subset of autism, so called Autoimmune Autistic Disorder, is
caused by a neuro-autoimmune pathogenesis triggered by viral infection (Singh, 2009).
Increased neuroglial response, characterized by astroglial and microglial activation, has
been demonstrated in the post-mortem brain tissue of autistics (Vargas et aI., 2005). Such
neuroglial activation indicates an immune response of the central nervous system (CNS)
representing an overall neuroinflammatory scenario which, argued here, may typify this
disorder in some individuals. This is relevant for the current study, as cases of PDD-NOS
and cases diagnosed with co-morbid autoimmunity were excluded. Obviously,
neuroinflammation can occur in the absence of an auto-immune response.
The immune system affects the CNS primarily through cytokines and
chemokines; diverse groups of regulatory proteins that mediate inflammation, immunity,
and hemopoiesis. Levels of the proinflammatory cytokines TNF-a and IL-6 are
significantly increased in brain tissue of some ASD patients when compared to controls
(Li et aI., 2009). Increased levels of proinflammatory cytokines TNF-a, IL 1-~, IL-2, IL-6,

and IFN-y are present in the peripheral blood mononuclear cells (PBMC) of some
children with ASD (Jyonouchi et aI., 2001; Molloy et aI., 2006). A neuro-inflammatory
process is shown in the cerebral cortex, cerebellum, and CSF of some autistic individuals,
and cytokine expression profiling indicates that macrophage chemo-attractant protein
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MCP-l and

TGF-~l

are the most up-regulated cytokines in these brain tissue samples

(Vargas et aI., 2005).
Polymorphisms

III

the regulatory regIOns of cytokine genes effect expreSSIOn

levels and have been shown to play a role in a variety of diseases including asthma,
autoimmune diseases, periodontal diseases, diabetes, Alzheimer's disease, and coronary
heart disease (Yucesoy et aI., 2003). It is known that cytokine gene polymorphisms can
alter immune disease susceptibility, severity, and outcome (Keen, 2002b). Since some
polymorphisms directly impact protein expression, and some ASD is characterized by an
abnormal immune response demonstrated in cytokine expression systemically and in the
CNS, it is reasonable to conjecture that polymorphisms in cytokine genes are correlated
with ASD pathogenesis. Here, a model that involves immune activation and
inflammatory processes is proposed, not one necessarily contingent on autoimmunity.
To investigate the co-occurrence of cytokine polymorphisms and ASD, this study
was carried out to ascertain frequency-based differences between two ASD
endophenotypes and population controls for polymorphisms among a set of eleven
cytokine genes (ILIA, ILIB, IFNG, TGFBI, TNF, IL2, lIA, IL6, IL12B, and ILIO), two
cytokine receptors (lLIRI, lIAR), and one cytokine receptor antagonist (lLIRN) (see
Table 2 for more details)4. These genes represent cytokines from both the innate and
adaptive immune response systems. The results of this study may offer insight into
immune activation and its role in the pathogenesis of ASD.

4 Note: If referring to the protein, a hyphen is used; if referring to a gene, no hyphen is
used. For example, ItA is the gene name, while IL-4 refers to the cytokine protein. Also,
cytokine names use the Greek nomenclature, while gene names do not. For example,
IFNG refers to the interferon gamma gene, while IFN-y indicates the cytokine.
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Table 2. Cytokine SNP name, chromosome locus and RS number
Gene
ILiA
ILiB
ILiRi
ILiRN
IL2
lIA
lIAR
IL6
ILiO
ILi2B
IFNG
TGFBi
TNF

Polymorphism*
Chromosome locus
-889C-T
2q14
-511 C-T
2q14
+3962 C-T
+1970 C-T
2q12
mspa1 11100 C -T
2q14
-330T-G
4q26-q27
+166 G-T
-1098T-G
-590C-T
5q31.1
-33 T-C
+1902G-A
16p12.1~11.2
-174G-C
7p21
nt565 G-A
-1082A-G
-819 C-T
1q31-q32
-592C-A
-1188 A-C
5q31.1-q33.1
12q24.1
+874T-A
codon 10 C-T
19q13
codon 25 G-C
-308 G-A
6p21.3
-238G-A

dbSNPID
rs1800587
rs16944
rsl143634
rs2234650
rs315952
rs2069762
rs2069763
rs2243248
rs2243250
rs2070874
rs1801275
rs1800795
rs1800797
rs1800896
rs1800871
rs1800872
rs3212227
rs2430561
rs1800470
rs1800471
rs1800629
rs361525

*Alleles to the left of the arrow are ancestral and those to the right are derived
SNP information was retrieved from the dbSNP (build 119,
http://www.ncbi.nlm.nih.gov/SNP; accessed March 2011)

Materials and Methods
ASD Samples and Sources
DNA samples of ASD participants came from two sources: 23 participants were
from Coriell Cell Repositories (http://ccr.coriell.org/autism/) and 26 autistic/Asperger's
participants were recruited for the study by Dr. Lonnie Sears in the Department of
Pediatrics at the University of Louisville Hospital. All ASD samples fit the diagnostic
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criteria of the Diagnostic and Statistical Manual-IV, as confirmed by the Autism
Diagnostic Interview-Revised (C. Lord et aI., 1994). Of the 49 ASD patients, 37 were
autistic, six were autistic with co-morbid mental retardation, and six were diagnosed with
Asperger's disorder. Of the six female ASD patients, two were diagnosed as autistic comorbid with mental retardation, two were autistic, and two were diagnosed with
Asperger's disorder. Potential participants with autism were excluded if they had any
patent genetic disorder such as fragile-X syndrome or tuberous sclerosis; evidence of
seizure disorder or autoimmunity also precluded participation. Exclusions were based on
medical and neurological histories and examination. This study was approved by the
Institutional Review Board of the University of Louisville (IRB 284.07).

Control Samples and Sources
DNA samples were obtained from amalgamated population surveys (Middleton et
aI., 2003). Data was verified in the original articles prior to inclusion in the present study.
Populations were chosen to reflect a general European sample given the constraints of
populations available. Specifically, population data was chosen from Germany, Ireland,
England, Italy, and several regional samples of Caucasians in the United States. Not
surprisingly, complete data for all cytokines reported for the ASD participants were not
available for all population controls (see Table 3 for details).
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Table 3. Allele and genotype frequencies at 22 SNP loci in ASD participants and controls
Gene

SNP

ILIA

-889 C-T
-511 C-T
+3962 C-T
+1970 C-T
mspal 11100 T-C
-330T-G
+166 G-T
-1098 T-G
-590C-T
-33 C-T
+1902A-G
-174 G-C
nt565 G-A
-1082A-G
-819 C-T
-592C-A
-1188 A-C
+874T-A
codon 10 T-C
codon 25 G-C
-308 G-A
-238 G-A

ILIB
ILIRI
ILIRN
IL2
lIA
lIAR
IL6
ILID
ILI2B
IFNG
TGFBI
TNF

Sample size
Control ASD
976
39
1241
48
540
47
540
49
540
49
816
47
540
47
540
45
1505
46
540
44
540
49
540
49
2505
49
2650
48
1172
48
2407
48
631
43
351
47
890
46
888
43
2360
49
540
49

Minor allele frequency (%)
Control
ASD
29.7
29.5
34.4
35.4
24.4
26.6
33.1
45.9
27.9
33.7
30.4
27.7
30.2
31.9
7.7
10.0
13.7
20.7
12.8
20.5
21.3
23.5
39.7
40.8
39.9
39.8
47.9
49.0
22.5
18.8
23.4
21.9
20.7
26.7
47.7
40.4
39.7
43.5
7.7
10.5
16.2
20.4
6.9
6.1

CC
CC
CC
CC
TT
TT
GG
IT

CC
CC
AA
GG
GG
AA
CC
CC
AA
AA
IT

GG
GG
GG

Control
48.5
42.1
57.4
43.5
51.3
48.0
49.4
85.0
74.6
75.7
62.0
37.0
35.8
26.8
60.0
59.0
62.6
25.4
35.5
85.7
70.1
86.7

ASD
53.8
37.5
53.2
28.6
38.8
53.2
48.9
80.0
67.4
68.2
59.2
34.7
34.7
16.7
64.6
62.5
51.2
34.0
28.3
81.4
63.3
87.8

Genotype frequency (%)
Control ASD
43.6 33.3
CT
CT
47.0 54.2
36.5 40.4
CT
46.9 51.0
CT
41.7 55.1
TC
43.1
38.3
TG
40.7 38.3
GT
14.6 20.0
TG
CT
23.6 23.9
23.0 22.7
CT
AG
33.3 34.7
GA
46.5 49.0
48.5 51.9
GC
AG
50.6 68.8
CT
35.0 33.3
35.1
31.3
CA
33.4 44.2
AC
53.8 51.1
AT
49.7 56.5
TC
16.3
13.3
GC
27.4 32.7
GA
13.0 12.2
GA

TT
IT
IT
IT

CC
GG
IT

GG
IT
IT

GG
AA
CC
GG
IT

AA
CC
IT

CC
CC
AA
AA

Control
7.9
10.9
6.1
9.6
7.0
8.8
9.8
0.4
1.9
1.3
4.6
16.5
15.7
22.6
5.0
5.8
4.0
20.8
14.8
1.0
2.5
0.4

ASD
12.8
8.3
6.4
20.4
6.1
8.5
12.8
0.0
8.7
9.1
6.1
16.3
14.3
14.6
2.1
6.3
4.7
14.9
15.2
2.3
4.1
0.0

......
r-

DNA Isolation and Amplification
Samples collected using buccal swabs at the University of Louisville were
isolated using a standard phenol-chloroform extraction and ethanol precipitation. The
Cytokine Genotyping PCR Kit (Invitrogen, Carlsbad, CA) was used to ascertain
genotypes reported in Table 2.

Statistical Analysis
Genotype, minor allele frequencies, and tests of Hardy-Weinberg equilibrium
were calculated using Excel. While the SNP data for the ASD participants could be
linked within individuals, the controls were based on population data. Therefore, each
SNP was tested individually with logistic regression in R (R Development, 2011).
Genotype was encoded using orthogonal polynomials, such that the linear coefficient
could be interpreted as the log-odds ratio as in the Cochran-Armitage test, assuming the
alleles are co-dominant. The quadratic term accounted for any deviation from codominance. Statistical significance was corrected for multiple comparisons with a false
discovery rate of q*

= 0.1

according to the method of Benjamini and Hochberg

(Benjamini & Hochberg, 1995).

Results
The distributions of allele and genotype frequencies at 22 SNP loci in ASD
participants and controls are found in Table 3. When carefully examining the table,
several items of interest are apparent. The ILl family is found closely clustered on
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chromosome 2q13. This may be of potential interest from the perspective of population
genomics. A review of the table frequencies of minor alleles and genotypes reveals
relative congruency across the five ILl loci except for ILIRI. The difference between the
minor allele frequency for cases versus controls is rather large, and the relative
frequencies of the different homozygotes vary. The fact that the minor allele frequency
for this one locus among the family of ILl loci differs between cases and controls and not
at the other four ILl loci suggests a possible association between ILIRI SNPs and ASD.
Scanning down the minor allele frequencies, two SNPs (-590 and -33) for IrA seem to
vary between cases and controls, and similarly differ in one of the homozygotes. This
pattern of differences implies that the IrA -590 T and -33 T constitute a linked haplotype;
though this was unable to be tested due to the use of population controls. Of particular
interest are the results for ILl a -1082. There is very little difference between the minor
allele frequencies for cases and controls, but consideration of the genotype frequencies
suggests that the cases may be out of Hardy-Weinberg equilibrium.

Tests for Hardy-Weinberg Equilibrium
Tests of Hardy-Weinberg equilibrium are found in Table 4. While two SNPs, IrA
-33 and ILIa -1082, are statistically significant at p < .05 and thus not considered in
Hardy-Weinberg equilibrium; none of the results are statistically significant when the
Benjamini-Hochberg correction is applied. Although this is true, the results of ILIa 1082 are brought to the attention of the reader. IL-1O is one of the more important antiinflammatory cytokines; it has been associated with several diseases likely due to
immune activation, and ILIa -1082 is the locus that exerts the greatest control of gene
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expreSSIOn. There was a lower frequency of the higher expression ILlO -1082 GG
genotype among ASD patients in this study. Though not statistically significant in this
data set following a multiple-test correction, a possible relationship between ILlO -1082
and ASD should be further explored.

Risk Estimates for Genotype Association
The estimates of odds ratios for the association of ASD and individual SNPs show
that genotype frequencies for the proinflammatory ILl Rl + 1970 and anti-inflammatory
IIA -590 and IIA -33 alleles are significantly different in ASD patients compared to

controls even after the Benjamini-Hochberg correction (Table 5). All three of these SNPs
are negatively associated with ASD; that is, they are not protective. None of the tests for
the linear coefficient of the overall trend of the genotypes (e.g., the Cochran-Armitage
test) was significant. Due to sample zeros, the quadratic term was excluded from the
models for IIA -1098 and TNF -238: None of the autistics were homozygous for the
minor allele at these loci, and maximum likelihood estimates of the parameters would
diverge to

CIJ

were both the linear and quadratic terms included.
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Table 4. Hardy-Weinberg table for raw data
Gene

SNP

ILIA

-889 C-T
-511 C-T
+3962 C-T
+1970C-T
mspal 11100 T-C
-330T-G
+166G-T
-1098 T-G
-590C-T
-33 C-T
+1902 A-G
-174 G-C
nt565 G-A
-1082A-G
-819 C-T
-592C -A
-1188 A-C
+874T-A
codon IOT-C
codon 25 G-C
-308 G-A
-238 G-A

ILIB
ILIRI
ILIRN
IL2

lIA
lIAR
IL6

ILIO
ILI2B
IFNG
TGFBI
TNF

Sample size
Control Autistic
976
39
48
1241
540
47
540
49
49
540
816
47
540
47
540
45
46
1505
44
540
540
49
540
49
49
2505
2650
48
48
1172
2407
48
43
631
47
351
890
46
888
43
2360
49
540
49

Chi-Square
Control
ASD
1.898677548 1.530522007
2.124070384 1.643534762
0.046411601 0.056275809
1.930570968 0.035469831
0.764843801 2.681770178
0.323264051 0.085809257
0.597612045 0.667976972
0.397807863 0.555555556
0.008231917 3.371032001
0.496365467 4.021224476
0.012818436 0.054920288
0.460495721 0.010078319
0.294291928 0.266799465
0.503812276 6.77187697
0.015056333 0.414465515
0.881695966 0.362081494
0.19007596 0.685462593
2.150933539 0.173143771
1.319108458 1.031284593
3.060845721 0.716507246
0.198168534 0.001172724
0.075516242 0.206787635
------_.-

P-Value
ASD
Control
0.216034228
0.168226476
0.145000787 0.199841262
0.829429339 0.812482065
0.16469607 0.850614552
0.381816907 0.101502877
0.569652641 0.769573999
0.439490599 0.413757818
0.528223545 0.456056544
0.927707203 0.066352195
0.481101474 0.044931087
0.909857305 0.814712666
0.497392389 0.920034048
0.587483201 0.605486845
0.477829815 0.00926054
0.902341299 0.519711645
0.347737594 0.547352494
0.662853404 0.407712023
0.67733282
0.142483281
0.309857384
0.250752305
0.080199936 0.397291992
0.656203231 0.972681736
0.783468218 0.649296959

In
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Table 5. Results of the logistic regression analysis
Gene

SNP

ILIA

-889 C~T
-511 C~T
+3962 C~T
+1970 C~T
mspa1 11100 T ~C

ILIB
ILIRI
ILIRN
IL2
lIA

-330T~G

+166 G~T
-1098 T~G
-590C~T

-33
lIAR
IL6

C~T

+1902A~G
-174G~C

nt565

G~A

-1082A~G

ILI0

-819 C~T

IL12B
IFNG

-1188 A~C

-592C~A

TGFBI
TNF

+874T~A

codon 10 T~C
codon 25 G~C
-308 G~A
-238 G~A

Linear trend (odds
MLE
CI
[0.69, 1.93]
1.21
[0.50, 1.53]
0.93
[0.51, 1.85]
1.06
1.80
[1.15,2.76]
[0.51, 1.89]
1.07
[0.50, 1.53]
0.93
[0.68, 1.79]
1.15
[0.60,2.72]
1.35
[1.21,3.77]
2.27
[1.40,5.23]
2.79
1.18
[0.56, 2.07]
[0.60, 1.48]
0.97
[0.65, 1.57]
1.03
[0.60, 1.71]
1.02
[0.15, 1.36]
0.62
1.01
[0.49, 1.70]
[0.47,2.30]
1.20
[0.44, 1.15]
0.73
1.14
[0.69, 1.79]
[0.36, 3.66]
1.55
[0.54,2.51]
1.36
[0.33, 1.95]
0.88

ratio)
P
0.458
0.790
0.851
0.00795 0.827
0.803
0.571
0.426
0.00362 0.001710.610
0.891
0.901
0.939
0.351
0.981
0.637
0.190
0.597
0.409
0.411
0.782

PQ
0.138
0.333
0.766
0.793
0.200
0.679
0.584
n.t.
0.0897
0.0446
0.852
0.709
0.772
0.0152
0.534
0.651
0.508
0.918
0.462
0.778
0.951
n.t.

MLE: maximum likelihood estimate; CI: 95 % confidence interval; P Q : P-value for the
quadratic term; n.t.: not testable; -: statistically significant at q * = 0.1.

76

Discussion
This is the first study to examine the association between ASD and cytokine
polymorphisms. Previous research has focused on the measurement of cytokine levels in
the brain, CSF, and blood rather than genotyping the polymorphic sites that are putatively
responsible for relative inter-individual levels of circulating cytokine concentrations. The
present study demonstrates positive association with ASD for cytokine polymorphisms
lIA -590T, lIA -33T, and ILIRI +1970T.

The Issue of Multiple Comparisons
The fundamental issue with using something like a cytokine panel, where many
SNPs are scored simultaneously, is the theoretical statistical concern of multiple
comparisons. If one considers that the probability of obtaining a statistically significant
result by chance is 1- 0.95 K , where K is the number of tests conducted, appropriately
interpreting the results of multiple comparisons can quickly become an issue. In this
particular case, 22 SNPs in 13 genes were tested. Considering only the 13 genes, there is
roughly a 50% chance of obtaining a significant result by chance. In order to correct for
multiple comparisons, the method of Benjamini and Hochberg was used. However,
statistically correcting for multiple comparisons, while important, can obviate some
important data, and further fails to account for the importance of population history and
the hazards of operating without a model of biologic plausibility.
Consider two possible models for the contribution of particular genes (or SNPs in
those genes) influencing inflammation and the etiology of ASD.

One model is that

independent spontaneous mutations are occurring in individuals in any of multiple genes
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contributing to the initiation or maintenance of inflammation. This model presumes that
the regulation of inflammation can be broken in multiple ways; all leading to
inflammation contributing to the suite of behaviors that are clinically distributed along
the autistic spectrum. Arguably, it would be unlikely that in a small group of autistics the
same SNP would be shared among sufficient individuals to achieve statistical
significance5 . The consequence of using this model is that while it might be proven that
inflammation is a common contributing factor to the etiology of autism, it would be
difficult to prove the genetic contributions of particular SNPs.
Another possible model is that autistics share immune gene SNPs in common as a
function of population structure and shared ancestry. In this model, theoretical constraints
would preclude historically negative selection coefficients, and the contribution of
particular genes to the etiology of autism would emerge only in conducive environmental
circumstances. Environmental factors interacting with genetic variability may be the in
utero influence of industrial pollutants or exposure to infectious disease. Admittedly, a

logical weakness of this model is that if individuals are sharing SNPs in inflammation
genes they would also be sharing SNPs in genes not related to inflammation; and the
problem of multiple comparisons becomes once again significant. This model does,
however, allow the possibility that when considering the contribution of the immune
system to the etiology of ASD, some cytokine genes (and their SNPs) would be more
likely than other cytokine genes to be implicated depending on their roles in the immune
activation process. Herein it is argued that IL4 and ILIRI are two genes playing

However, certain regions of the genome do seem particularly susceptible to mutation.
An example is ILlO, which lies in a region of high recombination, and has a relatively
large number of SNPs in its promoter region.

5
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fundamental roles in the immune activation process, and putatively in the etiology or
progression of ASD.

IL-4 and IL-IR functions in the immune system and CNS
Of interest are the specific functions of IL-4 and IL-IR within the immune system
and CNS. IL-4 activates cytotoxic immunity in response to virus-infected cells, and
drives T cell differentiation toward the Th2 phenotype. It is released in allergic and
inflammatory responses, and rescues T lymphocytes from apoptosis (Vella et aI., 1997).
IL-4 enhances the antigen-presenting capacity of B cells by stimulating MHC class II
molecules, B7, CD40, surface IgM, and low-affinity IgE receptor expression (Borish &
Steinke, 2003). Research with adult murine neural progenitor cells shows that IL-4activated

microglia preferentially induce

oligodendrogenesis

over neurogenesis

(Butovsky et aI., 2006). This study also demonstrates that both neuro- and
oligodendrogenesis activated by microglia are blocked in the presence of LPS (a proxy
for bacterial infection). These results are of particular interest, given that microglia are
activated in various brain regions of autistic patients where enlarged cerebral white
matter volumes are also present and recent evidence indicates an association between
increasing radiate white matter volume and impairment (Courchesne et aI., 2001; Herbert
et aI., 2004; Mostofsky et al., 2007). IL-4 production in peripheral blood mononuclear
cells of autistic children is significantly higher than that of normal controls (Molloy et aI.,
2006). Increased IL-4 levels are present in the sera of patients with asthma, and it was
recently established that a SNP in the IL-4 gene confers susceptibility to the disease
(Amirzargar et aI., 2009). Therefore, evidence of the increased IL-4 production,
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chronically activated microglial cells, elevated white matter volumes, and significantly
different genotypic frequencies in the llA promotor region which are capable of effecting
protein expression levels suggests that this cytokine may relay susceptibility to autism.
In the brain, IL-I plays a role in long-term potentiation, and in mouse and rat
studies it has been demonstrated that most IL-I receptors are found in the hippocampus, a
region that is morphologically enlarged in autistic individuals (Schumann et aI., 2004).
Rodent studies demonstrate that IL-I is induced in the hippocampus during the learning
process, and that exogenously administered IL-I increases memory function while
blockage of IL-I signaling impairs memory function (Yirmiya & Goshen, 2011). In the
immune system, IL-I plays a significant role in the induction of Th 17 cells, which have
been shown to provide protection against bacterial infection in mice (Acosta-Rodriguez
et aI., 2007). While studies of IL-I expression in the CNS of autistic individuals do not
yield significant differences when compared to controls, systemic evidence indicates that
increased IL-l levels are present in the plasma, whole blood, and peripheral blood
mononuclear cells of autistic patients (Ashwood et aI., 20 II; Croonenberghs et aI.,
2002a; Jyonouchi et al" 2001). Micro-array evidence suggests that the gene pair ILIRlIILI-R2 plays a crucial role in mediating dendritic cell functions during the primary
immune response (Zhong et aI., 2009). If polymorphisms in the ILIRI gene cause
deficient dendritic cell functioning in the systemic immune system, this would impair the
antigen presenting abilities of these cells and weaken communication between the innate
and adaptive immune systems. Functionally, autistic patients demonstrate impaired
performance on neuropsychological tasks involving hippocampal circuits when compared
to controls (Loveland et aI., 2008). While IL-l expression has not been investigated in the
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hippocampus of autistic individuals, future research in this area may link IL-l levels in
this region to behavioral impairment. Given the findings of this study, which demonstrate
significantly different genotypic frequencies in the ILIR gene of autistic individuals, this
cytokine may play significant roles in the pathogenesis of ASD.

Conclusion
The original impetus for this research project was to investigate the possible
association of varIOUS cytokine SNPs with autism. It has been reasonably wellestablished that inflammation, at some level, is involved in the etiology and progression
of ASD. The thirteen genes in the genotyping panel used in this study are arguably some
of more significant genes involved in the initiation and/or mediation of inflammation.
Much remains to be learned about the intricacies of the expression dynamics of the
cytokine network. Much more remains to be learned about the pleiotropic nature of
cytokine expression at different times in the life history of the organism and in response
to different kinds of immune challenges.
ASD is a complex disease with a pathogenesis that involves the genetic variation
of a number of contributing genes in addition to the action of environmental factors.
Changes in gene expression, coordination, and patterns of interactions of cytokine gene
products likely influence the development of ASD, but the mechanisms remain to be
revealed. Simultaneously, epigenetic factors play contributing roles by affecting the
network of interaction of critical genes and their proteins. This is the first reported study
to examine the association between ASD and cytokine polymorphisms. SNPs in cytokine
genes and their promoters may alter cytokine expression and cause an overall imbalance
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in the regulation of the immune system, resulting in an inflammatory profile seen both in
the central nervous system and systemically in autistic individuals. The present study
demonstrates positive association with ASD for cytokine polymorphisms lIA (-590T),
lIA (-33T) and ILIRI (+1970T), and adds to the growing literature that a dysregulated

immune response may be central to the pathogenesis of certain endophenotypes within
ASD.
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CHAPTER III

Cytokine Transcriptional Expression in the Cerebral Cortex of Autistic Subjects

Introduction
Autism is a pervasive neurodevelopmental disorder typically manifesting in the
first three years of life, and diagnosis depends on a triad of impairments in social
interaction, communication and cognition (American Psychiatric Association, 2000).
Autism is idiopathic, although evidence indicates a complex etiology with an underlying
genetic susceptibility likely acting in concert with immunological dysfunctions and
unidentified environmental exposures (Ashwood et aI., 2006; Persico & Bourgeron,
2006). Post-mortem studies reveal neurobiological abnormalities in cytoarchitectural and
neuronal organization, suggesting altered neuronal maturation and/or defective cortical
organization may play roles in the pathogenesis of autism (Bauman & Kemper, 2003;
Casanova et aI., 2002; Pardo & Eberhart, 2007). Evidence indicates that maternal
immune

activation

during

embryonic

development

could

account

for

these

neuropathological abnormalities and this activation may be cytokine dependent (Shi et
aI., 2007; Shi et aI., 2009; S. E. Smith et aI., 2007). Cytokines are regulatory proteins that
mediate inflammation, immunity and hemopoiesis, and facilitate communication between
the immune and central nervous systems (CNS) (Borish & Steinke, 2003). Patients with
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autism have altered cytokine levels in plasma, peripheral blood mononuclear cells, whole
blood supernatant, cerebrospinal fluid, and brain tissue (Croonenberghs et aI., 2002a;
Jyonouchi et aI., 2001; Li et aI., 2009; Molloy et aI., 2006; Vargas et aI., 2005).
To investigate neuroinflammatory mechanisms, the transcription of four cytokines
(TGFB-l, IL-IB, IL-6, and TNFa) and one chemokine (lL-8) was analyzed in five regions
of the cerebral cortex of postmortem brains using reverse transcriptase-initiated real-time
PCR on eight autistic-control pairs. This technique permits monitoring product formation,
and allows precise quantification of baseline mRNA. Sample size is limited by RNA
quality and tissue availability but is sufficient to uncover robust changes that may
characterize the neuropathology typifying autism. This study reveals differential
transcription of cytokine genes in various cortical regions of autistic brains compared to
neurotypical controls, and proposes novel molecular mechanisms yet uninvestigated
which may be involved in the pathogenesis of ASD.

Materials and Methods

Human Brain Samples
Autistic and control brain specimens were obtained through The Autism Tissue
Program (ATP) (http://www.brainbank.org) from the Harvard Brain Tissue Resource
Center, supported in part by PHS grant R-240MH068855. Formaldehyde-fixed sections
of Brodmann Areas (BA) 4, 9,17,22 and 46 from eight individuals with autism and eight
control individuals were analyzed. Cortical areas correspond to primary motor cortex
(BA 4), dorsolateral prefrontal cortex (BA 9 and 46), primary visual cortex (BA 17), and
superior temporal gyruslWernicke's area (BA 22). Review of the ATP clinical database
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resulted in the 16 matched subjects presented in this study (Table 6), and no significant
difference in mean age or postmortem interval (PMI) was present between groups. Tissue
recovery followed an institutionally approved informed consent procedure and was
coordinated nationally by the ATP and NIMHlNINDS Harvard Brain Tissue Resource
Center.

Table 6. Autistic and control samples
Diagnosis ATPID#
Control
Control
Control
Control
Control
Control
Control
Control

AN12552
AN03334
AN08678
AN12137
AN19760
AN05475
AM07932
AN04432

Sex Age PMI

Cause of Death

M
M
M
M
M
M
M
M

Multiple Injuries
Possible Pulmonary Embolism
Hepatic Encephalopathy
Asphyxia
Unknown
Heart Attack
Accident
Central Hepatic Laceration

Control MEAN
Autism
Autism
Autism
Autism
Autism
Autism
Autism
Autism

AN08792
AN00493
AN01093
AN06746
AN00764
AN01971
AN01613
AN11989

Autism MEAN

M
M
M
M
M
M
M
M

56
36
40
31
28
39
17
22
33.6
30
27
56
44
20
39
29
30
34.4

24
26.02
25.25
32.92
23.25
UK
6.5
12
21.4
20.3
8.3
19.48
30.8
23.7
31.5
UK
16.06
21.4

Gastrointestinal bleeding
Drowning
Anoxic Encephalopathy
Acute Myocardial Infarction
Accident
Hospitalized with Pneumonia
Heart Attack
Congestive Heart Failure

PMI: Post-mortem interval (hours), UK: Unknown. Autism Tissue Program identifier is
depicted by ATP ID#. The age and postmortem interval were not significantly different
across groups (two-tailed t-test =0.9 and 0.99, respectively).
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Sample Preparation
Tissue was dissected for gray matter specimens approximately 40-80 /-lg, and total
RNA was isolated using the Ambion Recoverall™ Total Nucleic Acid Isolation Kit for
FFPE Samples (Applied Biosystems, Foster City, CA) according to the manufacturer's
protocol. The integrity of RNA was assessed on an ND-1000 Spectrophotometer V3.3
(Nanodrop Technologies, Wilmington, DE).

Two-step RT-PCR
Total RNA extractions were reverse transcribed into cDNA using the TaqMan
Reverse Transcription Reagent Kit (Applied Biosystems) and primed with the standard
random hexamer according to the protocol. The reverse transcription (RT) reaction was
performed with a DNA Thermal Cycler 480 (PerkinElmer, Fremont, CA) as follows:
25°C for 10 min, 48°C for 30 min and 95°C for 5 min. Real-Time PCR was performed in
low-transmissiveness 96-well reaction plates (AbiPrism; Applied Biosystems) using
SYBR@ Green PCR Master Mix (Applied Biosystems) as the reporter. All reactions were
conducted as follows: 50°C for 2 min, 95°C for 10 min, 95°C for 15 s (40 cycles), 60°C
for 1 min (40 cycles), 95°C for 15 s, 60°C for 30 s, and 95°C for 15 s with a 7300 RealTime PCR System (Applied Biosystems). Amplified cellular GAPDH from all samples
served as a housekeeping gene to normalize expression and monitor reproducibility.
Primers were synthesized by Alpha DNA (Montreal, Quebec) and their sequences follow:
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TGF~-l:

Forward: 5' -CAACAATTCCTGGCGATACCT-3'
Reverse: 5' -GCTAAGGCGAAAGCCCTCAAT -3'
IL-8:
Forward: 5' -CAAAGAACTGAGAGTGATTGAGAGTG-3'
Reverse: 5' -CCCTACAACAGACCCACACA-3'
IL-l~:

Forward: 5'-TCTACACCAATGCCCAACTG-3'
Reverse: 5' -AGCGAATGACAGAGGGTTTC-3'
TNFa:
Forward: 5'-AGGCGGTGCTTGTTCCTCA-3'
Reverse: 5' -GTTCGAGAAGATGA TCTGACTGCC-3'
IL-6:
Forward: 5' -CACACAGACAGCCACTCACCTC-3'
Reverse: 5' -CTGCCAGTGCCTCTTTGCTG-3'
GAPDH:
Forward: 5' -GAGTCAACGGATTTGGTCGT -3'
Reverse: 5' -TGGAAGATGGTGATGGGATT -3'

Qualitative Analysis
The instrument on-board software 7300 System SDS (Applied Biosystems)
generated output data, which was transferred to an MS Excel spreadsheet for analysis.
The software generated a log-linear calibration graph which plotted primer copy number

87

from run-off transcript for each sample's mRNA against the number of cycles it took for
each reaction product to exceed a preset florescence threshold (Cr ). To obtain
quantitative measurements, Cr values for each sample were performed in duplicate and
compared with those obtained in the standard curve fitted to points of the calibration
graph. All readings were standardized to the amplification values obtained for the
GAPDH housekeeping gene:

L1CT,x

= CT,x -

CT,GAPDH

where x is the target gene. Thus, the

number of each transcript is expressed relative to GAPDH. Relative change in expression
of gene x between the autistic and neurotypical case is

MCT,x

= L1C;~tism -

the corresponding fold change in expression was calculated using

L1Ci,~ntrol, and

TMCT,X

(Fu et al.,

2006).

Statistical Analysis
The relative expression of gene x (x

= TNF,IL6,

TGFBi, ILiB, or IL8) in the

tissue sample from participant i, Brodmann area j was analyzed using the mixed-effects
linear model
L1C(i,j)
T,x

= fJo,x
R + R D + R,T R
fJl,x i
I-' 2, x j

+

1/

I i,x

+ Cij ,x
C'

D is a dummy variable encoding diagnostic category (Di = 0.5 for autistic i, and Di = -0.5
otherwise). Encoding ensures that the coefficient

Ihx

is an estimate of

L1L1CT x

over all

five Brodmann areas. Rj is a dummy variable encoding BA j; the Yi,x are independent,
identically distributed random intercepts with zero mean; and the
identically distributed residuals.
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cij,x

are independent,

Prior to fitting, preliminary analysis with the LmRA toolbox (Verboven &
Hubert, 2005) robustly examined the raw CT data for outliers. The linear models were fit
using R software packages NLME (Pinheiro et aI., 2010) and contrast (Kuhn et aI., 2010).
Goodness of fit was established by comparing standardized residuals to a standard normal
distribution using the Kolmogorov-Smirnov D statistic.
The mixed effects linear model used here accounts for the correlation between
measurements of different Brodmann areas within the same brain. Five univariate
Wilcoxon tests would implicitly assume that those different measurements were
independent, necessitating a correction for multiple comparisons. The linear model, on
the other hand, assumes a particular (normal) distribution of observed data within groups.
Preliminary non-parametric tests for outliers in the data, as well as post-hoc tests of the
residuals of the fit indicate that this assumption is not validated. Thus, the mixed effects
linear model was considered the best choice for this data analysis and applied
accordingly.

Results
The investigated control and autistic brains showed no significant difference in
age (t14

= 0.13,

two-tailed p

= 0.900) or post-mortem interval

(t12

= 0.006, P = 0.995)

between autistic and comparison subgroups. Preliminary analysis detected no statistical
outliers among the CT values. Post hoc test of the residuals found no significant deviation
from the expected standard normal distribution, with the greatest Kolmogorov-Smirnov
D = 0.127 and its associated p = 0.214, in the model fit for TNF. Average MCT,x was

not significantly different from zero for any of the target genes: TNF (F1,14
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= 0.207, P =

0.656), IL6 (F 1,14
0.665, p

= 0.308, p = 0.587), TGFBI

(F 1,14

= 0.024, p = 0.879), ILIB (F 1,14 =

=0.428) or IL8 (F 1,14 =0.074, p = 0.789). Relative expression of all five target

genes also did not vary significantly by Brodmann area, nor was there any significant
variation of MCT,x with Brodmann area. Mean transcriptional expression levels for
autistic and control samples and fold change values by cortical region are shown in Table
7 below.
Table 7. Differential gene expression in autistic patients
Target
Gene

IL6

TGFBI

IL8

TNF

ILIB

BAa

4
9
17
22
46
4
9
17
22
46
4
9
17
22
46
4
9
17
22
46
4
9
17
22
46

Relative expressionb
Aut.
C.C.

-10.9
-11.0
-11.1
-11.0
-11.1
0.136
0.258
0.440
0.168
0.420
-1.20
-1.17
-1.19
-1.16
-1.07
-4.25
-4.26
-4.38
-4.32
-4.05
0.96
1.17
1.29
0.92
1.14

-10.8
-10.8
-10.8
-11.0
-10.8
0.258
0.266
0.260
-0.015
0.113
-1.32
-1.33
-1.28
-1.51
-1.44
-4.03
-4.09
-4.06
-4.33
-3.92
2.21
2.00
1.98
1.63
1.95

Fold change
Mean
95 % CI

1.14 [0.66, 1.97]
1.19 [0.69,2.04]
1.22 [0.70,2.11]
1.04 [0.60, 1.81]
1.17 [0.68, 2.02]
1.09 [0.44,2.71]
1.01 [0.41, 2.49]
0.88 [0.35,2.21]
0.88 [0.35, 2.22]
0.81 [0.32, 2.02]
0.92 [0.31, 2.68]
0.89 [0.31, 2.60]
0.93 [0.32,2.74]
0.78 [0.27,2.30]
0.77 [0.26, 2.27]
1.17 [0.70, 1.93]
1.12 [0.68, 1.84]
1.25 [0.75, 2.08]
0.99 [0.59, 1.68]
1.09 [0.66, 1.82]
2.37 [0.54, 10.31]
1.78 [0.41, 7.65]
1.61 [0.37, 7.06]
1.64 [0.37, 7.28]
1.75 [0.40, 7.66]

a. Brodmann area
b. CT,target - Cr,GAPDH; estimated from the fixed effects of the linear models; Aut = autism;
C.c. =comparison clients
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Discussion
Results indicate altered cytokine expression in the cortex of autistic patients,
where gene transcripts TNF-a, IL-6,

TGF~-1, IL-1~,

and IL-8 are heterogeneously

expressed in different cortical regions when compared to controls. BA 22 showed a
differential pattern of expression in which gene transcript levels were down-regulated
compared to controls for all transcripts except IL-1~, which appeared up-regulated. IL-1 ~
showed the most up-regulation throughout all five cortical regions, with BA 4 showing a
two-fold increase compared to control samples. Though sample size was limited and no
statistical significance was determined, these findings suggest that transcriptional changes
may be related to the neuropathology present in autism.
The CNS immune profile is only beginning to be revealed in autistic patients,
where studies demonstrate an active and ongoing neuroinflammatory process in the
cerebrospinal fluid, cerebral cortex, white matter and cerebellum (Chez et aI., 2007; 1. T.
Morgan et aI., 2010; Vargas et aI., 2005). Very few studies have investigated cytokine
expression profiles within the brain tissue of autistic subjects.

TGF~-1

was found to be

significantly increased in cortical and cerebellar tissue when compared to controls, while
proinflammatory cytokines including IL-6 were significantly increased in the anterior
cingulate gyrus (Vargas et aI., 2005). Significant increases in several proinflammatory
cytokines, including IL-6, IL-8, IFNy, and TNFa, have also been demonstrated in the
frontal cortex of ASD patients (Li et aI., 2009). These postmortem studies indicate that
cytokine expression at the translational level is significantly different in various cortical
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regIOns of autistic subjects when compared to neurotypical controls6 . Interestingly,
although we analyze different cortical regIOns than the abovementioned translational
studies, our transcriptional results did not indicate significant differences in cytokine
transcripts of autistic subjects when compared to matched controls. These contradictory
results suggest that post-transcriptional regulatory mechanisms may playa role in ASD
pathogenesis. Indeed, investigations of post-transcriptional gene regulatory networks in
patients with ASD suggest that epigenetic factors, including dysregulation of microRNA
expression, may contribute to observed alterations in gene expression and lead to the
pathophysiological conditions that underlie autism (Sarachana et aI., 2010).
Immune transcriptome alterations in the temporal cortex of ASD patients have
been previously identified, and microarray studies reveal that greater transcript variability
is present in the brains of autistic subjects when compared to controls (Garbett et aI.,
2008). Whether this variability is a reflection of the heterogeneity of the disorder or an
inherent characteristic related to the core neuropathology is not known, but represents a
serious limitation when drawing conclusions in studies of gene expression in the brain
tissue of autistic subjects. Another confounding factor that should be considered when
reviewing results of gene expression in the postmortem human brain involves agonal
conditions associated with the samples provided. A majority of the patients contained in

Investigators should be cautious when interpreting these results. Multiple investigators
have reported that brain samples from the Autism Tissue Program show extensive
degradation, which was discovered after several research groups had already published
studies using the same tissue. Brain banks need to focus their efforts on establishing
quality assessment measures prior to distributing brain samples to research laboratories.
In the meantime, investigators should be cautious drawing conclusions from their
findings, and perform quality control assessments on tissue to determine whether their
evidence represents a core pathology associated with ASD or rather is a remnant of poor
tissue quality.

6
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the ATP database died of hypoxic lesions that were ischemic in origin including near
death experiences associated with drowning. Ischemic reperfusion injuries of this kind
result in inflammation and oxidative damage primarily targeting white matter, and are
defined neuropathologic ally by astrogliosis and microgliosis. Thus, there is a distinct
possibility that the cytokine profiles relayed in Vargas et aI., 2005, Li et aI., 2009,
Morgan et aI., 2010, and in the current study are attributed to conditions associated with
near death experiences rather than the autism neuropathology. There is evidence that
hypoxia has significant effects on RNA integrity in postmortem brain samples (Tomita et
aI., 2004), and as three of our samples died of injuries that were hypoxic in origin, this
should be considered a limitation in the present study. Future studies regarding
neuroinflammatory mechanisms in autism should match samples not only based on age,
gender and PMI, but also on agonal conditions in order to determine if gene expression
profiles truly are associated with autism or are simply remnants of the cause of death.
In conclusion, multiple studies demonstrate that an altered immune profile

IS

present in the brain tissue of autistic individuals. While only a few studies have attempted
to characterize the cytokine translational profile within various cortical regions, they have
all revealed significant alterations in cytokine expression in autism. This is the first study
to report on cytokine transcriptional expression in autism cortical tissue. Surprisingly,
transcriptional results did not reflect those of translational results reported by other
groups. This finding has led the investigators herein to conclude that post-transcriptional
regulatory mechanisms may be putatively responsible for the observed differences in
translational cytokine expression reported by other groups. The increased expression
variability among ASD subjects indicates that the disorder may be heterogeneous on the
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molecular level, further supporting the idea that the interplay between the environment
and genetics are significant etiological components in this multifactorial disorder.
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CHAPTER IV

Intravenous Glutathione Administration and Cytokine Expression Analysis in the
Plasma of Autistic Children

Introduction
Autism spectrum disorders (ASD) are complex neurodevelopmental disabilities
defined on the basis of a triad of behavioral impairments in three domains: socialization,
language, and stereotyped behaviors (American Psychiatric Association, 2000).
Accumulating evidence over the last few decades indicates that immune dysregulation is
another key feature of the ASD pathology. Gastro-intestinal (GI) abnormalities, including
inflammation, are frequently reported in children with autism, however the prevalence of
these GI symptoms is inconsistent and varies widely across studies (Horvath & Perman,
2002; Molloy & Manning-Courtney, 2003; Taylor et aI., 2002; Valicenti-McDermott et
aI., 2006). As a result, many non-traditional treatments have been proposed for autistic
patients, including heavy metal detoxification and nutritional therapies (Aman, 2005). No
evidence-based studies support these kinds of interventions in the treatment of autism,
although anecdotal reports claim that they are effective (Christison & Ivany, 2006; Levy
& Hyman, 2003). Systemic and CNS inflammation is present in patients diagnosed with

autism, and persist despite oral or intravenous steroid or immunoglobulin therapies
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(Handen et aI., 2009). Thus, it is undetermined whether there is a pathophysiological
relationship between autism and GI abnormalities or if these are just unrelated co-existing
conditions that affect a subset of patients. Regardless, there is clearly some force that is
driving the ongoing inflammatory response in ASD.
Oxidative stress, defined as an imbalance between the production and
manifestation of reactive oxygen species (ROS) and the body's ability to detoxify
reactive intermediates or repair the damage caused by them, has been demonstrated in the
peripheral tissues of children with autism (Chauhan & Chauhan, 2006; Keller & Persico,
2003). Increased nitric oxide levels in red blood cells and higher antioxidant enzyme
activity have been reported in autistic patients (Sogut et aI., 2003). Chemically, oxidative
stress is associated with increased production of oxidizing species or a significant
decrease

In

the capability of antioxidant defenses, such as glutathione (Schafer &

Buettner, 2001). The cys-containing tripeptide glutathione is the primary determinant of
redox status in all human cells because it is a thiol-containing compound that is critical
for heavy metal detoxification and elimination. Significantly lower levels of glutathione
peroxidase, an antioxidant enzyme, and plasma glutathione, as well as higher ratios of
oxidized glutathione to reduced glutathione, have been reported in autistic children and
indicate that a disruption in antioxidant defense mechanisms is associated with the
disorder (James et aI., 2004; James et aI., 2006; Yorbik et aI., 2002).
Oxidative stress occurs in the brain tissue of various neurodegenerative diseases
including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis,
Huntington's disease, and stroke (Beal, 2002; Neumann et aI., 2008; M. A. Smith et aI.,
1994; Takeda et aI., 2000). The brain is particularly vulnerable to oxidative stress during
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early development because it has low levels of antioxidants, high energy requirements,
and a high fat and iron content (Juurlink & Paterson, 1998). Astrocytes serve as
reservoirs for glutathione within the brain, and provide the cysteine necessary for thiol
metabolism in human neuronal cells. There is growing evidence supporting the role of
oxidative stress in the brain tissue of autistic subjects (Sajdel-Sulkowska et aI., 2008).
Postmortem immunohistochemical studies have demonstrated that oxidative damage,
evidenced by lipid modification, is localized primarily in the white matter of patients with
autism, suggesting that axons may be the sites of primary oxidative damage within the
brain of these individuals (Evans et aI., 2008). This evidence is particularly relevant to
the global underconnectivity deficits demonstrated in ASD (Casanova et aI., 2009), and
may account for these white matter changes from a molecular perspective.
Glutathione is the main intracellular antioxidant and protects neurons from
oxidative stress (Siesjo et aI., 1980). Thus, impaired glutathione production contributes to
oxidative stress, which could delay the clearance of heavy metals or xenobiotics.
Glutathione deficiency has been associated with Parkinson's disease, schizophrenia,
ADHD, HN, and inflammatory bowel disease (Do et al., 2000; Dvorakova et aI., 2006;
Iantomasi et aI., 1994; Jenner, 1993; Kalebic et aI., 1991). Although studies of
glutathione expression in postmortem brain tissue of autistic subjects remain to be
performed, systemic studies clearly indicate dramatically lower glutathione in ASD,
which suggests that autistic children may have more difficulty resisting infection,
resolving inflammation, and detoxifying environmental contaminants (James et aI.,
2006). The control of intracellular redox status is vital to proper cellular function via
transcription factor-regulated intracellular signaling pathways that culminate in the
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transcription of proinflammatory cytokines (see Figure 1 below). During oxidative stress
and inflammation, transcription factors including NF-K13 are activated and lead to the upregulation of proinflammatory genes (Arrigo, 1999; Mercurio & Manning, 1999). The
redox status of glutathione in particular is essential for the transcriptional regulation of
these proinflammatory genes, and increasing intracellular glutathione has been shown to
decrease the release of cytokines and chemokines by decreasing NF-K13 activation
(Rahman et ai., 2005). Specifically, the NF-K13 family of transcription factors is known to
activate the expression of

IL-1~,

TNF-a, IL-6 and IL-8 (Akira & Kishimoto, 1997;

Gotoh & Cooper, 1998; Rahman & MacNee, 1998). Thus, given that intracellular
glutathione levels are low in ASD subjects (James et ai., 2006), it is expected that an over
abundance of pro inflammatory cytokines will be expressed systemically. Indeed, several
studies demonstrate that proinflammatory cytokine levels are significantly increased in
the plasma and whole blood of autistic individuals (Ashwood et ai., 2011; Croonenberghs
et ai., 2002a; Singh, 1996). In addition, increases in specific cytokine levels in autistic
children have been associated with more impaired communication and aberrant behaviors
(Ashwood et ai., 2011). In this study, it is proposed that peripheral administration of
exogenous glutathione in autistic children will result in a decrease of the expression of
pro inflammatory cytokines in plasma and improvements in behavioral outcome.
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Figure 1. Oxidative stress alters the intracellular concentrations of glutathione (GSH),
which modulates NF-lCB activation leading to the transcription of proinflammatory
cytokines.

Pro-inflammatory gene expression
TNF-a, IL-8, IL-1 P

It is challenging to determine how the immune-brain connection is responsible for

creating and maintaining the ongoing eNS inflammatory response and abnormal
metabolic profiles in autism. Exposures to environmentally toxic agents, disturbances in
redox homeostasis and perturbations in immune balance have all been proposed as
contributing factors to the pathophysiology of ASD. The cause of oxidative species in
autism is not known but could be a result of exposure to environmental toxins such as
heavy metals or infections during early development. It has been shown that chronic
methylmercury exposure in primate cortex leads to a large increase in activated
microglia, suggesting that heavy metal exposure may not only play an etiologic role in
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oxidative stress but also in microglia-based neuroinflammation which is evident in autism
(Charleston et aI., 1994; Vargas et aI., 2005). Additionally, thimerosal and inorganic
mercury lower glutathione levels in a dose-response fashion in cultured human neuronal
cells (Deth & Muratore, 2010). It is important to keep in mind that the production of ROS
occurs in the course of normal physiological processes, however oxidative stress occurs
when an overabundance of ROS causes cellular damage. The most important intracellular
determinant of redox status is glutathione, and depleted levels of glutathione in patients
with autism are an indication of oxidative stress (James et aI., 2004). It is proposed here
that weekly exogenous administration of glutathione will decrease the expression of
proinflammatory cytokines measured in the plasma of children with ASD, and be
correlated with behavioral improvement. In this way, modification of systemic
glutathione levels and thereby cytokine expression may offer molecular therapeutic
mechanisms in children diagnosed with ASD.

Materials and Methods

Subjects
Participants were enrolled in the study through the Kosair Charities Pediatric
Research Unit at Kosair Children's Hospital in Louisville, Kentucky. Children with
autism and severe behavior problems between the ages of 5 and 17 years old were invited
to participate in this research study through the Department of Pediatrics at the University
of Louisville Health Sciences Center, Weisskopf Child Evaluation Center, and Kosair
Children's Hospital. Participants included 19 children with ASD (mean age 8.1, 17
males). This study was approved by the University of Louisville institutional review
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board (GLUTATHIONE-KCPCRU-Ol; HSPPO #08.0220) and complied with all
requirements regarding human subjects. Parents gave informed consent. Prior to study
inclusion, the Autism Diagnostic Interview-Revised (ADI-R) was administered to
confirm that each patient met diagnostic criteria. Rating scales were administered at
designated times throughout the study per the protocol schedule to determine changes in
behavior with treatment. The Clinical Global Impressions Improvement (CGI-I) Scale
was completed to assess change in response to treatment. This assessment has been used
extensively in psychiatric treatment studies and has been shown to have good reliability
and validity.

Study Design
This was placebo-controlled and double-blind study, in which parents, study
doctors and research nurses did not know when each child received which treatment.
Patient participation lasted up to five months and included 18 study visits (including the
screening visit). Once diagnosis was confirmed, a pre-drug phase screening visit was
scheduled during which time written consent and a baseline blood specimen (-1
teaspoon) was obtained. Subjects were randomized to receive either glutathione or
placebo (normal saline) intravenously over 15 minutes on a weekly basis. Randomization
ensured that subjects received either glutathione or placebo in the first 2-month block and
then crossed over to the alternate treatment in the second 2-month block. There was one
week between the glutathione and placebo treatments during which time subjects did not
receive any study drug.
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During weeks 1-8, subjects received weekly injections of glutathione or placebo
(whichever they were randomized to during that 2-month block). At week 9, the subject
did not receive study drug and a blood specimen (-1 teaspoon) was collected. The subject
crossed over to the other treatment during weeks 10-17 and at week 18 the subject did not
receive study drug and a final blood specimen (-1 teaspoon) was obtained. Subject and
sample information is contained in Table 8 below.
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Table 8. Subject and sample information for glutathione study

Subject # Gender Age Collection Type Collection Date
002
003

M
M

10
9

004

M

6

005

M

7

006

F

6

009

M

9

010

M

10

013

M

7

014

M

7

015

F

11

016

M

8

017

M

11

018

M

6

020

M

6

021

M

8

022
023
024
025

M
M
M
M

6
7
11
9

Placebo
Glutathione
Glutathione
Placebo
Glutathione
Placebo
Baseline
Placebo
Glutathione
Baseline
Placebo
Glutathione
Baseline
Placebo
Glutathione
Baseline
Placebo
Glutathione
Baseline
Glutathione
Placebo
Baseline
Baseline
Placebo
Glutathione
Baseline
Glutathione
Placebo
Baseline
Placebo
Glutathione
Baseline
Placebo
Glutathione
Baseline
Placebo
Baseline
Baseline
Baseline
Baseline
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10/09/09
9125/09
09/04/09
11106/09
10/09/09
12/11109
08128/09
11106/09
01108/10
10123/09
12/31109
03/05/10
11106/09
01115/10
03/19/10
01129/10
04/09/10
06/11110
02/05/10
04/16/10
06/18/10
02/12/10
04/02/10
06/11/10
08/13/10
04/16/10
07/01110
09/03/10
04123/10
07/09/10
08127/10
09/17/10
11126/10
01128/10
10129/10
01107/11
02/18/11
12/03/10
02125/11
02/25/11

Sample preparation
For each subject, peripheral blood was collected in acid-citrate dextrose
Vacutainers (BD Biosciences; San Jose, CA), centrifuged at 2,000 rpm for 20 minutes at
room temperature, and the plasma harvested. Plasma was aliquoted and stored at -20°C
at the Kosair Charities Pediatric Clinical Research Unit facility. Plasma samples were
transplanted on ice every 2 months to the Molecular Anthropology and Population
Studies (MAPS) laboratory at the University of Louisville Health Sciences Center where
they were stored at -20°C until cytokine analysis.

Multiplex Analysis
Quantification of cytokines in the plasma were determined using human
multiplexing bead immunoassays (Invitrogen, Carlsbad, CA) that are based on sandwich
immunoassays that utilize Luminex® fluorescent-bead-based technology. Plasma samples
were run in concordance with the human cytokine 1O-plex assay

(Invitrogen) as

recommended by the manufacturer. The following cytokines were measured: Interleukin-
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(IL-lj3), IL-2, IL-4, IL-5, IL-6, IL-8, IL-1O, interferon-y (IFN-y), tumor necrosis

factor-a (TNF-a), and granulocyte macrophage-colony stimulating factor (GM-CSF).
Briefly, all samples were clarified by centrifugation (1,000 g for 10 min) prior to
analysis. 50 ilL of plasma was diluted 1: 1 in human cytokine 1O-plex assay diluent and
incubated with antibody-coupled beads for two hours at room temperature on an orbital
shaker at 500-600 rpm. Between each step the complexes were washed twice in wash
buffer (Invitrogen) and aspirated using a vacuum manifold. The beads were then
incubated with a biotinylated detector antibody for one hour before incubation with R-
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Phycoerythrin (streptavidin-RPE) for 30 minutes. Finally, the complexes were
resuspended in 100 ilL of wash buffer and analyzed using a flow-based Luminex® 1O0™
device (Luminex Corporation, Austin, TX). Sample cytokine concentrations were
calculated using a standard curve derived from the known reference cytokine
concentrations supplied by the manufacturer. A five-parameter algorithm model with a
weighted function (lIl) was used to calculate final concentrations and values are
expressed in pg/mL.

Statistical Analysis
Sample cytokine concentrations

III

pg/mL were estimated by inverting the

response curves, which were calculated using samples of known concentration provided
by the manufacturer. Mean MFI (maximum fluorescence intensity) for a gIven
concentration was modeled using a five-parameter logistic curve in the form
recommended by Liao and Liu (Liao & Liu, 2009):
MFI

= D + - -A-D
---[1 + (21/g -1)( ;. )b

g

]

The parameters were estimated by maximum likelihood, assuming that the observed MFI
followed a Poisson distribution. Cytokine concentrations between glutathione and
placebo phases were tested using the Wilcoxon signed rank test for matched pairs. In all
there were 11 matched pairs because one subject, #003, had glutathione data but no
placebo data. The null hypothesis for each cytokine was that there would be no difference
in concentration between placebo and glutathione phases. The alternative hypotheses
were that concentrations of pro-inflammatory cytokines would be reduced under
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glutathione treatment, and that other cytokine levels would differ in either direction from
their placebo values. P-values were corrected for multiple comparisons using the false
discovery rate (Benjamini & Hochberg, 1995). All calculations were performed using R
software version 2.10.0 (R Development, 2011).

Results
Cytokine levels for mne of the ten cytokines investigated did not differ
significantly between ASD patients who received placebo or glutathione administration
when the Benjamini Hochberg correction was applied (Table 9). Median plasma cytokine
levels were not calculable for GM-CSF as they were below the sensitivity limit of
detection by the Luminex® 1O0™ device. CGI-I test scores indicated that no change was
evaluated in most (8/12) autistic subjects in response to treatment with glutathione, and
two subject's behavior actually worsened with glutathione treatment (Table 10). One
subject, #009, reportedly had minimal improvement to little change in behavior with
glutathione administration and another subject, #004, had minimal to much improvement
in behavior with glutathione administration. Only two subjects had much improved
behavior reported on the CGI-I scale, and both of these values were associated with
placebo administration.
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Table 9. Comparison of median plasma cytokine levels in children with ASD at baseline,
placebo and glutathione blood draws
Cytokiner Baseline (n=15)
1.009
IFN-y
0.829
IL-l13
IL-2
0.427
IL-4
6.486
IL-5
0.120
IL-6
1.781
IL-8
5.940
IL-I0
0.550
1.032
TNFu

Placebo (n=13)
1.009
0.097
0.868
6.486
0.120
1.416
7.737
0.632
1.842

Glutathione (n=12)
1.129
0.995
0.321
6.332
0.122
1.689
8.339
0.865
0.821

P-value s (n=l1)
0.584
0.6637
0.4755
0.8311
0.0144
0.4492
0.7676
0.3326
0.6499

* All values are measured in pg/mL.
t GM-CSF concentrations are not reported as they were below the sensitivity limit of
detection.
§ P-values were calculated using the Wilcoxon rank test for matched pairs between
glutathione and placebo groups. When corrected for multiple comparisons using the false
discovery rate, none of these P-values reached statistical significance at p ::; 0.05.
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Table 10. Comparison of treatment and CGI-I scores

Subject # Treatment CGI-I Score'"
002
Placebo
2
003
Glutathione
4
Glutathione
2.5
004
Placebo
2
Glutathione
4
005
Placebo
4
Placebo
4
006
Glutathione
4
Placebo
3
009
Glutathione
3.5
Placebo
4
010
Glutathione
4
Placebo
2
013
Glutathione
5.5
Glutathione
4
014
Placebo
4
Placebo
4
016
Glutathione
4
Glutathione
4
017
Placebo
4
Placebo
5
018
Glutathione
5
Placebo
4
020
Glutathione
4
021
Placebo
4
* Compared to the patient's condition prior to initiation of treatment, this patient's
condition is rated as: 1=very much improved; 2=much improved; 3=minimally improved;
4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse
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Discussion
The etiology of ASD remains unknown, but accumulating evidence indicates that
there is an association between the ASD pathology and immune dysfunction.
Peripherally, altered T cell function, increased natural killer and monocyte cell activation,
and altered immunoglobulin profiles have been demonstrated in autistic individuals
(Ashwood & Wakefield, 2006; Croonenberghs et aI., 2002a; Enstrom et aI., 2009;
Saresella et aI., 2009; Sweeten et aI., 2004). Neuroinflammation is another characteristic
finding in autism (Vargas et aI., 2005). Oxidative damage, evidenced by plasma
glutathione deficiency, is also present in individuals with ASD (James et aI., 2004). The
mechanisms linking immune and neuropathological dysfunction in ASD are still unclear,
but evidence indicates that specific cytokines are capable of affecting neurodevelopment
and consequently, behavior. Cytokines and cytokine receptors in the CNS modulate
neural differentiation and plasticity. IL-6 is known to alter neuron proliferation and
survival, cortical neuron dendrite development, neural activity and long-term potentiation
(Gadient & Patterson, 1999; Juttler et aI., 2002; Mehler & Kessler, 1998). Other
cytokines,

including IL-1 p and TNF-a,

are

associated

with

neurite

growth,

oligodendrocyte toxicity, and regulation of homeostatic synaptic plasticity in the
hippocampus (Barker et aI., 2001; Cacci et aI., 2008; Munoz-Fernandez & Fresno, 1998).
Taken together, these findings suggest that cytokine dysregulation during the process of
neurodevelopment may have significant biological effects on neuronal development and
activity, which would negatively affect behavior.
It is likely that dysfunctional immune activity related to cytokines may affect the

core features of ASD. Significant elevation of IL-1 p, IL-6, IL-8 and IL-12p40 cytokine
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levels have been reported in the plasma of ASD children, and those with a regressive
form of ASD exhibited higher levels compared to children with non-regressive ASD
(Ashwood et aI., 2011). Furthermore, impairments in behavior were more pronounced as
certain cytokine levels increased, such that IL-4 levels were associated with greater
impairments in non-verbal communication, and significant associations were observed
between increased IL-6, IL-8, and IL-1 ~ levels and aberrant behaviors assessed by the
Aberrant Behavior Checklist (Ashwood et aI., 2011). Systemic modulation of cytokine
expression, therefore, may provide therapeutic applications for ASD children with severe
behavioral problems. Given that increasing intracellular glutathione levels has shown to
decrease the release of proinflammatory cytokines, exogenous glutathione treatment
offers a possible molecular therapy capable of putatively decreasing the expression of
those cytokines associated with aberrant behaviors, and ultimately resulting in behavioral
improvement in affected individuals.
In the present study, no significant changes in cytokine levels were reported in the
plasma of ASD children in response to treatment with glutathione. CGI-I scores assessed
throughout the study indicated that no significant changes in behavior were reported in
response to glutathione treatment. Glutathione is synthesized intracellularly from
glutamate, cysteine and glycine and is located largely within the cell (Voet & Voet,
2004). Exogenous administration of glutathione has been shown to have a very short half
life in human plasma, with rapid elimination and total clearance within approximately 10
minutes (Wendel & Cikryt, 1980). Thus, one possibility as to why cytokine expression
levels were not affected by exogenous glutathione administration could be that the
tripeptide was simply unable to permeate cell membranes due to it being metabolized so
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quickly within the bloodstream. Repleting glutathione levels with precursors of its
synthesis, such as N-acetyl-cysteine (NAC) or 2-oxothiazolidine-4-carboxylic acid may
prove to be more applicable treatments for increasing intracellular glutathione levels in
ASD as cysteine precursors are more cell-permeable, and may even be given orally
(Ghezzi, 2011). Modification of intracellular glutathione levels should still be considered
a possible molecular therapy capable of regulating systemic proinflammatory cytokine
expression and behavioral outcome in autistic children but not with exogenous
administration of glutathione itself. Instead, treatment should focus on precursors of
glutathione synthesis that are more permeable and metabolized more slowly, so that
changes in intracellular glutathione levels may have more long-lasting effects on NF-1d3
activation, proinflammatory cytokine expression, and ultimately behavior.
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CHAPTER V

Discussion

Review of Findings
Previous investigations demonstrate that abnormalities in cytokine translational
expression levels both systemically and in the CNS are one component of the immune
dysfunction that characterizes a subset of subjects with ASD. Some of these results are
contradictory (see Table 1) and could be a reflection of discrepancies between studies in
terms of classification and inclusionary criteria, methodology, co-morbidity presence,
immunization status, or co-administration of psychotropic medications. Contradictory
evidence could also confirm the presence of yet undetermined immune derived
endophenotypes within ASD. Immune activation during pregnancy alters cytokine
expression in maternal serum, the placenta, and fetal brain (Urakubo et aI., 2001;
Gillmore et aI., 2005; Depino, 2006). Evidence for CNS and immune dysfunction
involving cytokines in ASD led to the hypothesis purported here: that autism
pathogenesis is caused by the combination of genetic susceptibility in cytokine genes and
a second "hit" prenatal infectious scenario that occurs during specific periods of
development. The primary questions of each investigation are as follows:
1.) Do cytokine genes differ between autistic subjects and controls?
2.) Does cytokine transcriptional expression reflect previously qualified values of
translational expression in the cerebral cortex of autistic patients?
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3.) Can cytokine expression profiles and behavior be modified systemically with
glutathione administration in children with ASD?
The findings of each investigation are reviewed below.

SNP Investigation
Polymorphisms within the regulatory regions of cytokine genes are known to
effect expression levels and playa role in a variety of diseases. Thus, experimental aim 1
was to characterize different SNPs of selected candidate genes encoding cytokines in
autistic patients and controls to determine if any cytokine SNPs are associated with ASD.
Twenty-two single nucleotide polymorphisms (SNPs) in 11 cytokine genes (ILIA, lLIB,

IFNG, TGFB1, TNF, IL2, llA, IL6, IL12B, ILI0), two cytokine receptors (ILIRl, lIAR)
and one cytokine receptor antagonist (ILl RN) were analyzed. These genes were chosen
because they represent cytokines from both the innate and adaptive immune responses.
ASD DNA samples were obtained through an online cell repository and recruited for the
study at the University of Louisville Hospital. Control samples were obtained though
amalgamated population surveys available in an online database. Tests for HardyWeinberg equilibrium in both ASD and control cohorts indicated no statistically
significant p-values following a multiple-test correction, indicating that the two groups
were genetically comparable at the investigated locations. Results indicated that
pro inflammatory ILl Rl + 1970T, and anti-inflammatory llA -590T and -33T alleles are
significantly different in ASD patients compared to controls. This analysis suggests that
these cytokine SNPs may confer susceptibility to the disorder.
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Transcription Investigation
Recent research indicates that a neuroinflammatory scenarIO

present

In

individuals with autism, evidenced by abnormal cytokine translational expression

In

IS

various cortical regions (Li et aI., 2009; Vargas et aI., 2005). To investigate whether a
neuroinflammatory scenario is present at the transcriptional level, the mRNA profiles of
four cytokines

(TGF~-l, 1L-1~,

1L-6 and TNF-a) and one chemokine (1L-8) were

analyzed in five regions of the cerebral cortex (BA 4,9, 17,22, and 46) of postmortem
brains in eight autistic-control pairs. Autistic and control brain specimens were obtained
through the Autism Tissue Program and formaldehyde-fixed sections corresponded to
primary motor (BA 4), dorsolateral prefrontal (BA 9 and 46), primary visual (BA 17) and
superior temporallWernicke's (BA 22) cortical areas. No significant difference was found
in mean age or postmortem interval between autistic and control samples, indicating that
these groups were comparable. RNA extraction and reverse transcription reactions were
followed by real-time peR analysis, where GAPDH was used as the housekeeping gene.
Statistical analysis used a mixed effects linear model to account for correlation between
measurements of different Brodmann areas within the same brain, and results indicated
that relative expression of all five target genes did not vary significantly by cortical
location between autistic and control groups. Thus, these transcriptional results do not
indicate that a neuroinflammatory scenario is present at the transcriptional level. Because
increased levels of proinflammatory cytokines have been evidenced at the translational
level (see Table 1), the investigators herein concluded that post-transcriptional regulatory
mechanisms may be putatively responsible for the observed differences in translational
cytokine expression and warrant future study.
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Glutathione Investigation
Oxidative stress, evidenced by depleted levels of plasma glutathione, indicate that
a disruption in antioxidant defense mechanisms is associated with ASD (James et aI.,
2004). During oxidative stress and inflammation, transcription factors including NF-KB
are activated and lead to the up-regulation of proinflammatory cytokines. Increases in
several proinflammatory cytokines have been demonstrated in the plasma of ASD
children, and specific cytokine levels have been associated with more impaired
communication and aberrant behaviors (Ashwood et aI., 2011). It has been demonstrated
that increasing intracellular glutathione decreases the activation of NF-KB and results in a
decrease in the release of proinflammatory cytokines and chemokines (Rahman et aI.,
2005). To investigate whether cytokine expression can be modified systemically and
demonstrate a correlation with behavioral change, exogenous glutathione was
administered weekly in children with ASD and their plasma analyzed after a 2-month
treatment block. ASD children were recruited for this study through Kosair Charities
Pediatric Research Unit at Kosair Children's Hospital. This study was double-blind and
placebo controlled. Multiplex analysis of ten cytokines (GM-CSF, IL-l p, IL-2, IL-4, IL5, IL-6, IL-8, IL-lO, IFN-yand TNF-a) was performed using a Luminex® 100 device and
statistical analysis was performed using the Mann Whitney Wilcoxon test. Results
indicated that there was no significant difference in median cytokine concentrations for
nine of the ten cytokines investigated between ASD patients who received placebo or
glutathione administration. The median plasma cytokine concentrations of GM-CSF were
not calculable as they were below the sensitivity limit of detection by the Luminex®
100rM device. CGI-I test scores indicated that little to no change was evaluated in the

115

majority of autistic subjects in response to treatment with glutathione. As exogenous
administration of glutathione has been shown to have a very short half-life in human
plasma, it was concluded that cytokine expression levels were not affected by glutathione
administration because the tripeptide was simply unable to permeate cell membranes due
to its quick systemic elimination. Repleting glutathione levels with precursors of its
synthesis, such as N-acetyl-cysteine (NAC) or 2-oxothiazolidine-4-carboxylic acid may
prove to be more applicable treatments for increasing intracellular glutathione levels in
ASD, as these cysteine precursors are more cell-permeable (Ghezzi, 2011). This study
demonstrates that exogenous administration of glutathione is not sufficient to change
cytokine expression or aberrant behavior in ASD children. Changes in intracellular
glutathione levels mediated by cysteine precursors may have more long-lasting effects on
NF-KB activation, proinflammatory cytokine expression, and behavioral improvement.

Limitations of Findings
There are inherent statistical Issues with analyzing multiple polymorphic sites
within a genetic association study. One critical assumption in calculations of genotypic
frequency within a small sample cohort is that the estimated allele frequencies exactly
equal the underlying allele frequencies in the population being considered. In analyzing a
cytokine panel that contains 13 genes, there is roughly a 50% chance of obtaining a
significant result by chance. In order to correct for multiple comparisons, the Benjamini
Hochberg method was used. One limitation in the SNP study, therefore, is the possibility
that some important data may have been obviated during the application of the Benjamini
Hochberg correction. Another significant limitation was the number of ASD samples
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available for companson. Generally, statistical power increases with the number of
individuals studied in genotypic investigations, and ideal genotype studies involve
hundreds, if not thousands, of individuals (Purcell et aI., 2003). This investigation was
limited by the 49 ASD subjects that could be recruited from the University of Louisville
Hospital for participation during the duration of the study. Future investigations of
cytokine genetics in ASD should analyze sample sizes that include much larger sample
cohorts. Perhaps the most significant limitation contained in the SNP study is the
assumption that the contribution of particular cytokine SNPs influences inflammation and
the etiology of ASD equally. Just as ASD is heterogeneous, so too may be the etiological
mechanisms that confer susceptibility to the disorder. In other words, it is possible that
specific SNPs may be associated with the ASD SUbtypes or even with comorbidities that
so often occur within these SUbtypes. Thus, future research into any genotype analysis
regarding ASD should correlate subtype classification with SNP frequency for the most
robust conclusions.
Two significant limitations in the analysis of cytokine transcriptional profiles
included agonal conditions associated with the samples investigated, as well as issues of
tissue quality provided by the brain bank. These issues affect all immunocytochemical
studies of postmortem brain tissue from autistic subjects as investigators receive their
tissue from the same brain banks. Several of the autistic patients studied here and
elsewhere in the literature died of hypoxic lesions that were ischemic in origin. Ischemic
reperfusion injuries of this kind result in inflammation and the oxidative damage that
have been interpreted as characterizing an "autistic" neuropathology. Due to these issues
of agonal conditions associated with the samples available, it has not been definitively
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demonstrated that the neuroinflammation (and cytokine expression) present in these
tissues represents a core pathology associated with ASD or are rather secondary reactions
of this tissue associated with the cause of death. Additionally, multiple investigators who
received samples from the Autism Tissue Program have reported extensive degradation
in their tissue. While RNA quantification was performed prior to analysis in this
investigation, brain banks should focus their efforts on establishing quality assessment
measures prior to distributing tissue to research laboratories. Otherwise, remnants of poor
tissue quality may be inferred as pathological findings inherent to the ASD phenotype.
While there are several advantages of Luminex® analysis, there are also several
major problems. Baseline levels and detected levels of cytokines and other proteins
reported in studies that use Luminex technology are not the same as those observed by
ELISA techniques, or of other immunoassay kits (Loo et aI., 2011; Richens et aI., 2010).
Cytokine concentrations reported in the study of glutathione treatment did not match
those reported by other groups, and this is likely attributable to issues associated with the
specific kit being used for analysis. Different manufacturers use different buffering,
antibodies, and antibody sensitivities, and design their systems to start at higher or lower
baselines with more or less dynamic ranges in order to fit mUltiple assays into one kit.
Thus, cytokine levels cannot be compared across different manufacturers. Additionally,
under physiological conditions cytokines are generally low and many patients simply do
not have detectable cytokines in their plasma (de Jager et aI., 2009). GM-CSF was not
detectable in any of the plasma analyzed in the glutathione study. Although the cytokine
concentrations reported in this study did not match concentrations measured by other
groups, the baseline trends were similar and the reliability of the behavioral results is
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unequivocal. Exogenous glutathione administration does not ameliorate aberrant behavior
in autistic children and does not warrant therapeutic application in future research,
although modification of intracellular glutathione via the use of precursor molecules may
modify cytokine expression systemically in ASD children and result in improved
behavioral outcome.

Infection and inflammation during neurodevelopment: Common mechanisms in collateral
neuropathological damage
The fetal and neonatal Immune system has significant influences on the
developing CNS, and immune dysfunction during critical periods of development carries
serious neuropathological implications. Increasing evidence suggests that progressive
CNS damage is mediated by immune mechanisms, which may be contributing factors of
susceptibility in Alzheimer's disease, Parkinson's disease, and schizophrenia (LongSmith et aI., 2009; Porcellini et aI., 2010; Teixeira et aI., 2008). Review of current
research regarding neurodegeneration in the presence of neuroinflammation has led some
investigators to postulate that inflammatory and neurodegenerative pathologies of the
CNS share common molecular mechanisms (Zipp & Aktas, 2006). A classic example to
substantiate this theory can be found in studies of mUltiple sclerosis (MS). As a
demyelinating disease, previous research focused on oligodendrocyte and white matter
dysfunction. Subsequently, a century of histopathological study ignored the significance
of neuronal damage in MS, and it was not until the 1990s that early axonal pathologies in
the brains of MS patients were correlated with the degree of inflammation within a lesion
(Trapp et aI., 1998). Since then, infiltration of immune mediators into brain parenchyma
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has proven to have severely deleterious effects on neuronal tissue, as evidenced by
Wallerian degeneration in MS and neuronal apoptosis in bacterial meningitis and HIV
encephalopathy (Evangelou et aI., 2000; Kaul et aI., 2001; Nau & Bruck, 2002). Neuronal
damage was considered an indirect consequence of immune cell invasion since immune
cells did not usually have neuronal antigens and supposedly had no affinity for neurons
since they did not express major histocompatibility complex molecules. However, recent
evidence illustrates that activated immune cells actually do have the capacity to directly
target neurons and induce apoptosis in the inflamed brain (Giuliani et aI., 2003).
Perinatal exposure to infectious agents is linked to the pathogenesis of
neuropsychiatric disorders, but the mechanisms responsible for triggering the interaction
of the developing immune system and eNS which result in neurodevelopmental
disturbance have yet to be discovered. Epidemiological studies indicate that pregnant
women exposed to second-trimester respiratory infection have a significantly increased
risk for giving birth to a child that will develop schizophrenia (A. S. Brown, 2006).
Recent epidemiological research also indicates that early prenatal viral infection is
associated with ASD incidence (Altadottir et aI., 2010). Mouse models of intrauterine
infectionlinflammation cause cognitive deficits and neurodegeneration in their offspring
(Golan et aI., 2005). Inflammatory responses in the fetus and neonate have been shown to
contribute to cerebral white matter damage (Rezaie & Dean, 2002). Regarding autism,
several pre- and perinatal environmental exposures have been investigated using animal
models.
Although the use of animal models in investigations of neuropsychiatric disease is
controversial, measurements of behavioral, functional, anatomical, and histological
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characteristics parallel those found in humans and thus warrant review. Neonatal
infection with borna disease virus has been proposed as a model of neurodevelopmental
damage in rats that causes cytoarchitectural features and behavioral abnormalities similar
to those observed in children with autism (Hornig et aI., 1999). It has been proposed that
genetic susceptibility and exposure to a maternal immune response (rather than direct
infection of the fetus) are key players in the development of the autism phenotype
(Patterson, 2005). Offspring of pregnant mice who are injected with poly(l:C) to mimic
viral infection during early gestation show cerebellar pathologies consistent with those
seen in autism (Shi et aI., 2009). Systemic lipopolysaccharide (LPS) administration, a
commonly used experimental method designed to mimic bacterial infection, is known to
induce a peripheral inflammatory response that crosses the BBB and affects cognitive
function, dendritic structure, neuronal and glial proliferation, and in some cases produces
brain lesions (Hagberg & Mallard, 2005). There is substantial evidence to suggest that
proinflammatory cytokines, particularly IL-6, mediate the effects of maternal immune
activation on fetal brain development (S. E. Smith et aI., 2007). This should come as no
surprise, since it has been established that IL-6 effects brain development, the balance
between neurogenesis and gliogenesis, learning, memory, and the CNS response to injury
and disease (Bauer et aI., 2007; He et aI., 2005). Although the precise mechanisms of
fetal brain activation are yet undetermined, evidence indicates that immune mediators
have a significant role in the pathogenesis of autism and other neuropsychiatric disorders.
Neuroglial cells have significant roles in pre- and postnatal neurodevelopment,
thus prenatal neuroimmune disruption mediated by these cells can have profound
neurological ramifications. Microglia and astroglia, for example, are involved in cortical
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organization, neuroaxonal guidance and synaptic plasticity (Fields & Stevens-Graham,
2002). Astrocytes promote neuronal survival by releasing growth factors and controlling
uptake and removal of excitotoxic neurotransmitters from the synaptic microenvironment
(Nedergaard et aI., 2002). Astrocytes also produce several soluble factors that promote
synaptogenesis (Barres, 2008). In a study of human fetal astrocytes, TLR3 was the only
TLR with consistent expression in the resting state, which is known to bind double
stranded RNA in the presence of a viral infection (Farina et aI., 2005). Microglia have
roles in late embryonic brain development and early postnatal brain maturation by
modulating axon pathfinding and inducing neuronal apoptosis, phagocytosis, synapse
refinement, and innate immunity (Chamak et aI., 1994; Deverman & Patterson, 2009).
Embryonic microglia also secrete factors that are angiogenic, and depletion of microglia
during neonatal development reduces vascularization (Checchin et aI., 2006). All neural
and glial cell types in the developing CNS use cytokines for paracrine and autocrine
signaling. Since cytokines also serve as peripheral immune regulators, it follows that
neurodevelopmental processes are vulnerable to disruption by immune dysregulation
occurring prenatally in the form of maternal infection.
While neuronal damage is a characterizing feature of neuroinflammatory disease,
it is unclear whether neuroinflammation is a consequence of neurodegeneration or vice
versa. Molecular imaging techniques will be required to reveal the precise mechanisms

shared by each pathological condition. Although various neurological diseases differ
considerably etiologically and pathologically, many share crucial inflammatory processes
and immunological mechanisms that cause brain damage. Future research that targets
these processes will focus on the interface of immune response and neuronal
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homeostasis, and elucidate novel therapeutic applications for both neurodegenerative and
neurodevelopmental disorders.

Conclusions
ASD remams a pervasIve idiopathic neurodevelopmental disorder with a
characteristic neuropathology that is associated with specific behavioral deficits. While
accumulating evidence suggests that genetic and immunological components have
significant pathogenic roles in the development of ASD, inheritance patterns and immune
mechanisms are complex and difficult to interpret in a disease defined by heterogeneity.
In addition to the assorted behavioral manifestations on the spectrum, endophenotypes of
ASD based on genetic or immunologic markers may be associated with symptom severity
in subsequent studies. The notion that prenatal factors are involved in autism is currently
only speculative but has significant implications. Maternal and/or fetal immune activation
during critical periods of development may permanently alter the fetal immunological
balance and predispose the fetus to a lifetime of chronic inflammation both peripherally
and in the CNS. Collaboration will be imperative in future studies, which should be
performed on larger cohorts of ASD patients and aim to rectify inclusionary criteria for
both patient and control cases. Well-designed demonstrations of environmental influence
on neurodevelopmental trajectories will provide coherent and compelling molecular
mechanisms by which genetic susceptibility and prenatal immune challenge contribute to
the etiology of autism. Longitudinal studies that begin prior to diagnosis would provide
ideal means for understanding whether changes in cytokine expression play an etiologic
role or have predictive potential in ASD, or whether they are purely phenomenological.
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The investigations contained herein add to the growing research that implicates
cytokines in the pathogenesis of ASD. These novel findings indicate that SNPs in the
cytokine genes ILl Rl + 1970, and IIA -590 and -33 are significantly different in a cohort
of ASD patients when compared to controls, and suggest that the T allele at each of these
locations may confer susceptibility to ASD. In the first investigation of cytokine
transcriptional expression in the cortical tissue of autistic subjects, it was found that
cytokine mRNA expression does not differ significantly in the cortex of autistic patients
when compared to controls. Given that translational expression patterns do indicate
significant alterations in cytokine expression at the protein level, this work suggests that
post-transcriptional regulatory mechanisms may be responsible for altered translational
cytokine profiles in cortical tissue of autistic individuals. This was the first study to
investigate the use of exogenous glutathione as a therapeutic application in modifying
systemic cytokine expression and ameliorating aberrant behaviors associated with ASD.
Results indicated that exogenous glutathione administration is not sufficient for systemic
modification of cytokine expression and that, contrary to anecdotal reports, glutathione
does not improve aberrant behaviors in ASD subjects. Given the immunological and
neuropathological dysfunctions that characterize ASD, cytokines provide a molecular
pathway whereby basic cellular processes in both systems may be permanently altered
during prenatal development and ultimately culminate in the autistic phenotype, and the
results presented herein indicate that cytokine studies in ASD merit further investigation.
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APPENDIX
Diagnostic Criteria for Autism Spectrum Disorder according to the American
Psychiatric Association's Diagnostic and Statistical Manual-IV, Text Revision (DSMIV-TR).

Diagnostic Criteria for 299.00 Autistic Disorder
A.

1.

Six or more items from (1), (2), and (3), with at least two from (1), and one
each from (2) and (3):
qualitative impairment in social interaction, as manifested by at least
two of the following:

a.

marked impairment in the use of multiple nonverbal behaviors
such as eye-to-eye gaze, facial expression, body postures,
and gestures to regulate social interaction

b.

failure to develop peer relationships appropriate to
developmental level

c.

a lack of spontaneous seeking to share enjoyment, interests, or
achievements with other people (e.g., by a lack of showing,
bringing, or pointing out objects of interest)
d. lack of social or emotional reciprocity
2. qualitative impairments in communication as manifested by at least
one of the following:

a.

delay in, or total lack of, the development of spoken language
(not accompanied by an attempt to compensate through
alternative modes of communication such as gesture or
mime)

b.

in individuals with adequate speech, marked impairment in the
ability to initiate or sustain a conversation with others

c.

stereotyped and repetitive use of language or idiosyncratic
language

d.

lack of varied, spontaneous make-believe play or social imitative
play appropriate to developmental level
3. restricted repetitive and stereotyped patterns of behavior, interests,
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and activities, as manifested by at least one of the following:
a. encompassing preoccupation with one or more stereotyped
and restricted patterns of interest that is abnormal either in
intensity or focus
b.

apparently inflexible adherence to specific, nonfunctional
routines or rituals
c. stereotyped and repetitive motor manners (e.g., hand or
finger flapping or twisting, or complex whole-body
movements)
d. persistent preoccupation with parts of objects

B.

Delays or abnormal functioning in at least one of the following areas, with
onset prior to age 3 years: (1) social interaction, (2) language as used in social
communication, or (3) symbolic or imaginative play.

C.

The disturbance is not better accounted for by Rett's Disorder or Childhood
Disintegrative Disorder.

Diagnostic Criteria for 299.80 Asperger's Disorder
A.
1.

Qualitative impairment in social interaction, as manifested by at least two of
the following:
marked impairment in the use of multiple nonverbal behaviors such as
eye-to eye gaze, facial expression, body postures, and gestures to
regulate social interaction
2. failure to develop peer relationships appropriate to developmental
level
3. a lack of spontaneous seeking to share enjoyment, interests, or
achievements with other people (e.g., by a lack of showing,
bringing, or pointing out objects of interest to other people)
4. lack of social or emotional reciprocity

B.

Restricted repetitive and stereotyped patterns of behavior, interests and
activities, as manifested by at least one of the following:
1. encompassing preoccupation with one or more stereotyped and
restricted patterns of interest that is abnormal either in intensity of
focus
2. apparently inflexible adherence to specific, nonfunctional routines
or rituals
3. stereotyped and repetitive motor mannerisms (e.g., hand or finger
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flapping or twisting, or complex whole-body movements)
4. persistent preoccupation with parts of objects

C.

The disturbance causes clinically significant impairment in social,
occupational, or other important areas of functioning.

D.

There is no clinically significant general delay in language (e.g., single words
used by age 2 years, communicative phrases used by age 3 years).

E.

There is no clinically significant delay in cognitive development or in the
development of age-appropriate self-help skills, adaptive behavior (other than
in social interaction), and curiosity about the environment in childhood.

F.

Criteria are not met for another specific Pervasive Developmental Disorder or
Schizophrenia.

Diagnostic Criteria for 299.80 Pervasive Developmental Disorder Not Otherwise
Specified (Including Atypical Autism)
This category should be used when there is a severe and pervasive impairment in the
development of reciprocal social interaction associated with impairment in either
verbal or nonverbal communication skills or with the presence of stereotyped
behavior, interests, and activities, but the criteria are not met for a specific Pervasive
Developmental Disorder, Schizophrenia, Schizotypal Personality Disorder, or
Avoidant Personality Disorder. For example, this category includes "atypical autism" presentations that do not meet the criteria for Autistic Disorder because of late age at
onset, atypical symptomatology, or subthreshold symptomatology, or all of these.
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